Other specified and unspecified disorders of conjunctiva

H7_CONJUNAS

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — H11.8, H11.9 Hospital discharge: ICD-9 — 372[8-9] Cause of death: ICD-10 — H11.8, H11.9 Cause of death: ICD-9 — 372[8-9] 2 out of 7 registries used, show all original rules.	329
4. Check minimum number of events None	329
5. Include endpoints None	329
6. Filter based on genotype QC (FinnGen only)	329

Control definitions (FinnGen only)

Control exclude: H7_CONJUNCTIVA

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2

NAME	H7_CONJUNAS
CONTROL_EXCLUDE	H7_CONJUNCTIVA
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	H11[8-9]
HD_ICD_9	372[8-9]
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	H11[8-9]
COD_ICD_9	372[8-9]
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Other specified and unspecified disorders of conjunctiva based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	2409	1232	1163
Only index persons	2216	1153	1063
Unadjusted period prevalence (%)
Whole population	0.03	0.04	0.03
Only index persons	0.04	0.04	0.04
Median age at first event (years)
Whole population	49.21	51.60	46.86
Only index persons	50.48	52.87	47.88

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	329	184	145
Unadjusted period prevalence (%)	0.06	0.06	0.06
Median age at first event (years)	58.44	56.88	60.41

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
281: Matched controls
2811

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

H11.8

ICD-10 Finland

Other specified disorders of conjunctiva

2644.5

156.8

137

H11.9

ICD-10 Finland

Disorder of conjunctiva, unspecified

+∞

144.6

126

CFC00

NOMESCO Finland

Excision of lesion of conjunctiva

433.3

39.1

CFA20

NOMESCO Finland

Biopsy of conjunctiva

393.8

35.8

S01XA20

ATC

artificial tears and other indifferent preparations; ophthalmic

3.2

18.8

144

692

S01CA01

ATC

dexamethasone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)

3.0

15.5

123

585

D31.0

ICD-10 Finland

Benign neoplasm: Conjunctiva

21.6

15.4

3728X

ICD-9 Finland

Disorders of conjunctiva, Other disorders of conjunctiva

+∞

13.6

H11.4

ICD-10 Finland

Other conjunctival vascular disorders and cysts

+∞

13.6

S01GX01

ATC

cromoglicic acid; ophthalmic

3.8

13.6

194

CD2S4

NOMESCO Finland

Photography of eye

42.3

13.3

H04.10

ICD-10 Finland

Dry eye syndrome

4.6

12.7

111

CF2S4

NOMESCO Finland

Photography of conjunctiva

+∞

12.6

WX100

NOMESCO Finland

Conjunctival surface anesthesia

4.0

11.6

137

CBA10

NOMESCO Finland

Biopsy of eyelid

62.4

10.7

H11.0

ICD-10 Finland

Pterygium

+∞

10.5

3401

FHL

Removal of local modification or taking a specimen in the operating room

+∞

9.4

H10.3

ICD-10 Finland

Acute conjunctivitis, unspecified

5.9

9.2

H10.9

ICD-10 Finland

Conjunctivitis, unspecified

5.2

8.6

S01XA18

ATC

ciclosporin; ophthalmic

92.7

8.5

F02

ICPC

Red eye

6.2

7.8

H11.1

ICD-10 Finland

Conjunctival degenerations and deposits

+∞

7.3

CK2X4

NOMESCO Finland

Optical coherence tomography (OCT) of ocular fundus

3.5

7.3

102

H01.0

ICD-10 Finland

Blepharitis

4.8

7.3

Z96.1

ICD-10 Finland

Presence of intraocular lens

2.8

6.4

163

CFA12

NOMESCO Finland

Resection of conjunctiva

+∞

6.3

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(42870588) Differential panel, method unspecified - Blood

136

854

2.01

8.44

8.2

5.6

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

207

1534

1.94

7.62

10.9

9.4

4.00

4.06

e9/l

0.16

187

1349

(3000067) Parathyrin.intact [Mass/volume] in Serum or Plasma

183

2.55

6.81

5.8

3.8

99.54

76.25

ng/l

0.49

163

(3019198) Lymphocytes [#/volume] in Blood

184

1345

1.84

6.72

7.4

5.8

1.86

1.94

e9/l

0.31

166

1190

(3001604) Monocytes [#/volume] in Blood

180

1307

1.83

6.72

7.3

5.7

0.58

0.57

e9/l

0.18

158

1130

(3013115) Eosinophils [#/volume] in Blood

184

1349

1.83

6.62

7.7

6.0

0.17

0.18

e9/l

0.27

163

1192

(3024561) Albumin [Mass/volume] in Serum or Plasma

156

1088

1.83

6.61

7.7

4.5

35.54

35.62

g/l

0.06

140

1028

(3006315) Basophils [#/volume] in Blood

180

1313

1.82

6.56

7.4

5.7

0.04

e9/l

0.13

157

1137

(3011960) Natriuretic peptide B [Mass/volume] in Serum or Plasma

186

2.44

6.12

5.3

2.9

294.02

181.62

ng/l

0.57

170

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

162

1167

1.76

5.97

11.6

5.9

1.21

mmol/l

0.02

145

1074

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

500

1.91

5.76

5.4

3.7

958.23

246.25

ng/l

0.36

392

(3013826) Glucose [Moles/volume] in Serum or Plasma

203

1570

1.77

5.75

8.6

4.7

6.57

6.59

mmol/l

0.06

190

1453

(3007853) Bacteria identified in Skin by Aerobe culture

300

2.09

5.51

2.4

1.7

—

(3026493) Urate [Moles/volume] in Serum or Plasma

103

667

1.79

5.36

3.0

2.6

347.10

5510.85

umol/l

2.46

577

(3022096) Basophils/100 leukocytes in Blood

162

1194

1.70

5.30

7.5

5.9

0.57

0.66

1.37

148

1114

(3019069) Monocytes/100 leukocytes in Blood

166

1240

1.68

5.11

8.6

6.0

8.63

0.00

153

1166

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

295

2.04

5.04

2.1

1.7

—

(3002030) Lymphocytes/100 leukocytes in Blood

169

1274

1.67

4.98

8.1

5.8

28.03

27.93

0.04

155

1194

(3044941) Cell count panel - Synovial fluid

4.41

4.86

1.4

—

(3032080) INR in Blood by Coagulation assay

145

1057

1.66

4.82

10.6

7.9

1.15

1.24

inr

0.54

319

(3006504) Eosinophils/100 leukocytes in Blood

164

1234

1.66

4.81

8.4

5.7

2.66

2.70

0.08

151

1153

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

302

2707

2.41

4.80

21.2

13.5

21.11

23.91

mg/l

0.88

234

2107

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

302

1.99

4.72

2.1

1.7

—

(3018010) Neutrophils/100 leukocytes in Blood

166

1259

1.64

4.68

8.3

5.7

57.36

57.07

0.11

153

1185

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

106

716

1.71

4.66

4.1

3.1

1622.74

1188.76

ng/l

0.41

609

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

242

2035

1.72

4.44

10.1

7.4

77.87

80.02

u/l

0.37

233

1915

(43055120) Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection

3.20

4.43

15.9

4.8

547.80

616.75

iu/ml

—

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

239

2006

1.70

4.38

5.2

3.7

14.83

14.77

pmol/l

0.17

214

1806

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

412

1.82

4.32

2.2

1.8

—

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

3.37

4.24

1.5

1.3

—

(3027529) Toxoplasma gondii IgM Ab [Units/volume] in Serum

4.45

4.11

1.1

1.5

—

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

569

1.69

4.01

4.0

1.7

2.57

1.31

mg/l

0.41

440

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

164

1272

1.58

4.01

14.4

6.6

1.22

1.21

mmol/l

0.54

147

1077

(4010399)

194

2.08

3.97

1.6

1.4

—

(3015377) Calcium [Moles/volume] in Serum or Plasma

121

880

1.59

3.86

5.0

3.3

2.36

2.35

mmol/l

0.14

104

779

(3013707) Erythrocyte sedimentation rate by Westergren method

233

1974

1.62

3.80

4.9

3.8

11.04

12.07

mm/h

0.58

220

1816

(3000494) Fungus identified in Specimen by Culture

317

1.84

3.79

1.9

1.4

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

149

1143

1.55

3.75

3.3

2.6

139.25

118.33

ug/l

0.51

141

1051

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

135

1016

1.56

3.68

2.3

1.9

90.31

93.38

pmol/l

0.28

507

(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma

139

1057

1.55

3.60

2.5

2.3

78.82

77.16

nmol/l

0.28

122

949

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

276

2457

1.77

3.56

6.0

4.4

1.87

1.88

mu/l

0.05

249

2230

(3014959) Toxoplasma gondii IgG Ab [Units/volume] in Serum

3.94

3.54

2.2

2.8

—

(40768804) Tissue Pathology biopsy report

139

1060

1.54

3.54

2.4

2.0

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

176

1415

1.52

3.49

8.6

6.2

11.17

11.09

umol/l

0.04

168

1344

(40758558) Short blood count panel - Blood

679

1.58

3.38

7.3

6.9

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

192

1.98

3.36

1.5

1.6

—

(3042936) Bacteria identified in Isolate by Culture

369

1.73

3.35

3.2

2.0

—

(3044889) 12 lead EKG panel

222

1891

1.53

3.25

4.9

3.7

—

(3029634) Reagin Ab [Titer] in Serum by VDRL

3.65

3.22

1.8

2.3

—

(4306422)

3.65

3.22

1.4

1.3

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

2.81

3.20

1.3

—

(3047181) Lactate [Moles/volume] in Blood

2.46

3.12

6.4

11.4

1.15

1.36

mmol/l

0.73

(3018572) Chloride [Moles/volume] in Blood

2.76

3.10

7.0

13.8

104.13

104.80

mmol/l

0.17

(3039000) Anion gap in Blood

2.76

3.10

7.0

13.8

11.00

11.39

mmol/l

0.17

(3052851) Hemolysis interference index of Serum or Plasma

2.48

3.02

2.6

3.1

—

(3010130) Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma

2.82

3.02

2.1

1.4

114.00

99.45

u/ml

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

315

1.73

3.02

1.8

1.6

—

(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma

106

784

1.52

3.02

3.1

2.0

213.22

299.17

u/l

0.35

738

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

123

942

1.49

2.95

4.7

3.0

—

(3000991) Gas panel - Venous blood

210

1.86

2.89

19.2

7.1

—

(21493690) Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood

3.99

2.79

3.2

2.3

—

(44790047)

3.04

2.72

1.5

1.4

—

(44790048)

3.04

2.72

1.5

1.4

—

(44806118)

3.04

2.72

1.5

1.4

—

(44790049)

3.04

2.72

1.5

1.4

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

155

1.96

2.71

17.6

4.7

25.09

24.91

mmol/l

0.11

155

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

205

1753

1.45

2.68

3.3

3.0

—

(3019230) Fractional oxyhemoglobin in Venous blood

2.86

2.67

11.3

1.6

53.80

59.33

0.33

(3007461) Platelets [#/volume] in Blood

319

3032

2.71

2.66

29.2

19.6

242.00

248.06

e9/l

1.04

312

2957

(36304419) Bacteria [Presence] in Urine

730

1.49

2.65

4.0

2.8

—

(3026361) Erythrocytes [#/volume] in Blood

319

3035

2.68

2.59

29.1

19.6

4.49

4.51

e12/l

0.32

312

2951

(3010813) Leukocytes [#/volume] in Blood

319

3036

2.67

2.57

29.2

19.6

6.62

6.65

e9/l

0.10

312

2950

(3004789) Transferrin [Mass/volume] in Serum or Plasma

371

1.61

2.55

3.6

2.1

2.21

2.36

g/l

1.05

347

(40761511) CBC panel - Blood by Automated count

304

2843

1.91

2.55

19.7

12.4

—

(3019309) Folate [Moles/volume] in Red Blood Cells

472

1.56

2.55

1.8

1.7

986.18

1209.77

nmol/l

1.47

351

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

430

1.58

2.54

2.7

0.63

0.92

e6/l

0.44

240

(40763571) Iron/Transferrin [Ratio] in Serum or Plasma

347

1.63

2.53

3.7

2.2

23.93

23.60

0.05

306

(3019897) Erythrocyte distribution width [Ratio] by Automated count

3.53

2.50

1.8

1.6

13.63

13.07

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

129

1024

1.43

2.48

4.4

3.6

57.99

65.96

ng/l

0.08

708

(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma

2.52

2.48

2.1

1.5

—

(3037522) Nuclear Ab [Titer] in Serum

341

1.62

2.47

1.4

444.44

444.80

titre

—

(3018095) Leukocytes [#/volume] in Urine

120

942

1.43

2.45

4.5

3.6

18.54

79.82

e6/l

2.21

661

(3011397) Hemoglobin [Presence] in Urine by Test strip

608

1.49

2.42

3.5

3.4

—

(3016417) Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma

262

1.69

2.41

3.7

2.2

42.60

213.83

u/l

0.46

223

(3008536) Aspergillus sp Ab [Presence] in Serum

6.32

2.38

1.2

1.1

—

(3018418) pH of Serum or Plasma

104

799

1.44

2.37

7.4

3.9

7.40

0.05

151

(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method

2.92

2.32

1.1

—

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

135

1.92

2.29

24.4

11.4

—

(3011648) Oxygen content in Venous blood

3.95

2.26

2.3

1.4

9.71

11.27

—

(3007847) Interleukin 2 Receptor Soluble [Units/volume] in Serum or Plasma

3.95

2.26

1.7

3.1

596.57

652.50

u/ml

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

2.25

1.6

1.2

—

(3002256) Pathology report gross observation

333

1.59

2.24

1.4

1.2

—

(3002582) Erythrocytes [#/volume] in Urine

104

807

1.42

2.23

4.1

3.1

17.27

127.44

e6/l

0.76

617

(3017044) Thyrotropin receptor Ab [Units/volume] in Serum

2.47

2.22

3.6

1.6

4.55

6.40

iu/l

—

(3023368) Bacteria identified in Blood by Culture

717

1.44

2.21

7.3

4.3

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

2.56

2.21

1.2

—

(3030467) Casts [#/volume] in Urine by Automated count

737

1.43

2.18

4.1

2.9

0.35

0.48

e6/l

0.42

553

(3012095) Magnesium [Moles/volume] in Serum or Plasma

429

1.52

2.15

8.2

3.5

0.81

0.82

mmol/l

0.27

404

(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay

2.42

2.15

1.2

1.3

—

(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay

2.42

2.15

1.2

1.3

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

405

1.52

2.12

2.9

3.70

1.88

e6/l

0.70

218

(3051611) Lipemic interference index of Serum or Plasma

3.25

2.11

3.0

2.7

—

(3018171) Choriogonadotropin [Units/volume] in Serum or Plasma

2.13

2.11

1.6

2.2

620.04

5509.77

u/l

—

(3020059) Calcium [Moles/volume] corrected for albumin in Serum or Plasma

466

1.49

2.10

2.6

3.0

2.45

2.46

mmol/l

0.02

411

(3000850) Epithelial cells [#/volume] in Urine

556

1.45

2.05

3.5

2.5

3.75

5.08

e6/l

0.77

496

(3037467) Urinalysis macro (dipstick) panel - Urine

210

1849

1.38

2.04

5.6

3.9

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

2.17

1.95

2.1

1.5

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

148

1243

1.35

1.91

7.1

4.0

—

(3003327) Ova and parasites identified in Stool by Light microscopy

2.03

1.88

1.4

1.5

—

(3028369) Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection

2.90

1.87

1.4

1.3

—

(3026782) Osmolality of Urine

523

1.43

1.83

3.9

2.6

577.45

563.43

mosm/kgh2o

0.21

445

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

105

841

1.37

1.83

4.9

2.6

58.54

56.38

u/l

0.18

780

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

2.14

1.78

1.6

1.4

—

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

624

1.40

1.78

2.1

2.0

2.58

3.07

mg/l

1.85

542

(40760892) CBC W Ordered Manual Differential panel - Blood

615

1.40

1.78

6.7

4.8

—

(3048689) Calprotectin [Mass/mass] in Stool

326

1.52

1.78

1.5

2.2

109.03

131.33

ug/g

0.29

260

(3021952) Alkaline phosphatase isoenzymes [Enzymatic activity/volume] in Serum or Plasma by Heat stability

2.48

1.77

1.1

1.4

—

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

2.27

1.76

1.3

1.5

—

(3026389) Candida sp identified in Specimen by Organism specific culture

2.54

1.75

1.7

1.3

—

(36660697) Celiac disease serology panel - Serum

204

1.63

1.73

1.2

—

(21492711) Cytomegalovirus IgG Ab avidity [Presence] in Serum or Plasma by Immunoassay

2.96

1.73

1.1

1.2

—

(3021960) Folate [Moles/volume] in Serum or Plasma

618

1.39

1.73

1.8

1.5

24.33

20.86

nmol/l

0.59

515

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

2.11

1.73

1.1

1.4

—

(37020957) Sapovirus genogroups I+II+IV+V RNA [Presence] in Stool by NAA with probe detection

3.89

1.72

1.4

1.5

—

(42869457) Rotavirus RNA [Identifier] in Stool by NAA with probe detection

3.89

1.72

1.4

1.5

—

(3029023) Hepatitis E virus IgG Ab [Presence] in Serum by Immunoassay

3.89

1.72

1.0

1.1

—

(3002222) Hepatitis E virus IgM Ab [Presence] in Serum

3.89

1.72

1.0

1.1

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

2.07

1.67

1.6

1.4

—

(3002179) Metamyelocytes/100 leukocytes in Blood

190

1.64

1.67

4.3

4.0

0.40

0.54

—

(4035726)

248

1.55

1.64

1.5

1.4

—

(3028679) Herpes simplex virus Ab [Presence] in Serum

3.61

1.62

1.0

1.2

—

(1761868) Lipid panel - Serum or Plasma

1000

0.74

1.59

3.1

2.8

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

422

1.42

1.57

2.0

1.7

—

(3006922) Hepatitis E virus Ab [Presence] in Serum

3.37

1.53

1.0

1.1

—

(3024891) Influenza virus A+B Ag [Presence] in Specimen

1.99

1.51

1.1

1.2

—

(3045414) Leukocytes [Presence] in Urine

102

1.81

1.48

1.3

1.7

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

1.92

1.47

1.4

1.3

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

626

1.34

1.45

2.9

2.2

—

(3024928) Oxygen saturation in Venous blood

2.11

1.40

12.6

2.6

—

(3008898) HLA-B27 [Presence]

104

1.77

1.40

1.1

—

(4062490)

2.44

1.40

1.4

1.3

—

(3009542) Hematocrit [Volume Fraction] of Blood

267

2500

1.36

1.38

26.6

14.1

39.36

40.26

0.92

194

1846

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

2.16

1.35

1.4

1.5

—

(3016701) Glucose [Moles/volume] in Serum or Plasma --2 hours post dose glucose

0.00

1.34

0.0

1.4

—

7.66

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

283

2678

1.41

1.34

4.6

4.3

4.55

4.68

mmol/l

1.41

263

2482

(40768443) Skin Pathology biopsy report

106

1.74

1.32

1.0

1.2

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

277

2614

1.38

1.31

5.1

4.3

6.01

5.93

mmol/l

0.43

250

2385

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

282

2669

1.40

1.31

4.5

4.2

1.45

1.47

mmol/l

0.36

259

2462

(4268621)

2.53

1.31

2.5

2.4

—

(3027238) Thyroperoxidase Ab [Units/volume] in Serum or Plasma

170

1.57

1.30

1.1

1.2

146.20

122.89

iu/ml

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

2.39

1.30

1.1

—

(3041145) Herpes simplex virus IgM Ab [Presence] in Serum by Immunoassay

2.80

1.29

1.0

1.2

—

(4024509)

2.80

1.29

2.6

1.2

—

(3014148) Varicella zoster virus Ab [Titer] in Serum

2.32

1.27

1.0

1.2

—

(3014765) Yersinia sp identified in Stool by Organism specific culture

1.78

1.27

1.2

1.1

—

(3006418) Campylobacter sp identified in Tissue by Organism specific culture

1.78

1.27

1.2

1.1

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

298

1.43

1.26

1.9

1.7

—

(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay

2.25

1.25

1.0

1.2

—

(3011363) Streptococcus pneumoniae Ag [Presence] in Urine

2.66

1.22

1.2

—

(3051651) Icteric interference index of Serum or Plasma

2.66

1.22

3.0

2.8

—

(42529406) Shigella sp [Presence] in Stool by Culture

1.74

1.19

1.2

—

(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

201

1830

1.25

1.19

4.0

3.0

57.72

46.98

u/l

0.53

185

1713

(3009595) Pneumocystis jiroveci DNA [Presence] in Specimen by NAA with probe detection

2.33

1.19

1.7

1.5

—

(3017181) Myelocytes/100 leukocytes in Blood

216

1.48

1.19

4.6

4.0

1.00

1.15

—

(3044640) Blood type and Crossmatch panel - Blood

823

1.27

1.17

3.4

2.3

—

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

2.08

1.16

1.5

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

272

2573

1.33

1.16

4.1

3.9

1.31

1.29

mmol/l

0.21

247

2371

(3026008) Bacteria identified in Urine by Culture

759

1.28

1.15

3.2

2.9

—

(3027315) Oxygen [Partial pressure] in Blood

1.93

1.13

2.1

2.9

8.28

8.57

kpa

0.23

(3012501) Base excess in Blood by calculation

1.93

1.13

2.5

2.9

1.42

2.36

mmol/l

—

(3013290) Carbon dioxide [Partial pressure] in Blood

1.93

1.13

2.5

2.9

5.06

4.95

kpa

0.24

(3048929) Epstein Barr virus Ab [Presence] in Serum

1.74

1.13

1.5

1.3

—

(40768795) Lymph node Pathology biopsy report

2.36

1.13

1.3

1.1

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

511

1.31

1.12

2.1

1.8

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

650

1.28

1.11

3.4

4.2

25.02

22.02

0.63

291

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

503

1.31

1.10

1.6

1.5

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

153

1.54

1.09

1.8

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

286

2734

1.35

1.05

5.4

4.8

2.71

2.79

mmol/l

0.77

266

2521

(3019225) pH of Specimen

222

1.44

1.05

5.7

3.9

—

(3007930) Methemoglobin/Hemoglobin.total in Blood

1.66

1.05

7.9

9.0

1.14

0.89

2.74

(3012516) Albumin [Mass/volume] in Urine

740

1.26

1.03

4.2

3.1

634.94

406.60

mg/l

0.14

484

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

1.91

1.02

1.5

1.3

—

(3009508) Creatinine [Moles/volume] in Urine

808

1.25

1.01

4.2

2.9

6.85

7.66

mmol/l

1.57

680

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

165

1.49

1.00

1.3

—

(40766800) Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood

2.19

0.98

1.4

1.2

—

(3012441) Differential panel - Pleural fluid

0.00

0.97

0.0

1.5

—

(3020682) Albumin/Creatinine [Ratio] in Urine

784

1.24

0.96

5.2

3.8

4.34

9.43

mg/mmol

1.86

492

(3035350) Ketones [Presence] in Urine by Test strip

147

1315

1.21

0.96

4.0

3.4

0.00

estimate

0.00

265

(3046279) Procalcitonin [Mass/volume] in Serum or Plasma

109

1.59

0.95

3.3

2.0

7.24

3.77

ug/l

0.30

101

(3023421) Hepatitis B virus surface Ab [Units/volume] in Serum

1.64

0.95

1.3

1.5

241.00

236.43

miu/ml

—

(3000492) Spirometry study

236

1.39

0.94

1.6

1.4

—

(21494434) Karyotype in Bone marrow

2.24

0.94

1.7

1.0

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

126

1.54

0.93

8.3

2.2

1.17

1.27

0.13

126

(3014111) Lactate [Moles/volume] in Serum or Plasma

238

1.38

0.90

21.3

5.7

1.18

1.36

mmol/l

0.60

230

(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay

1.72

0.90

13.6

2.3

0.24

0.30

u/ml

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

1.74

0.87

1.5

1.3

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

320

1.32

0.86

9.0

6.9

—

(3014051) Protein [Presence] in Urine by Test strip

1.78

0.84

1.4

1.9

—

(3025159) Blasts/100 leukocytes in Blood

189

1.41

0.84

4.0

4.3

0.00

0.19

—

(3021589) Normoblasts [#/volume] in Blood

134

1202

1.19

0.83

10.5

9.2

0.00

e9/l

0.80

107

986

(3019060) Gas panel - Arterial blood

181

1.41

0.82

6.0

7.3

—

(3021788) Differential panel - Synovial fluid

1.89

0.82

1.5

1.4

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

131

1.48

0.80

2.2

—

(40761535) Cells panel - Urine sediment

217

1.37

0.80

5.2

3.1

—

(3009466) Valproate [Moles/volume] in Serum or Plasma

1.83

0.79

4.5

4.3

375.17

342.14

umol/l

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

1.68

0.79

1.4

1.1

—

(3019832) Treponema pallidum Ab [Presence] in Serum

253

1.34

0.79

1.6

1.7

—

(3019150) Specific gravity of Urine by Refractometry

574

1.23

0.78

4.1

3.6

1.01

1.02

kg/l

—

(3023081) Carboxyhemoglobin/Hemoglobin.total in Blood

1.54

0.77

8.3

9.0

1.66

1.61

0.13

(46236952) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)

210

1.36

0.77

1.7

2.6

61.90

67.09

ml/min/173m2

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

1.72

0.76

1.0

1.3

—

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

1.66

0.76

1.2

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

1.62

0.76

1.4

1.2

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

282

1.31

0.75

2.9

3.5

—

(3021601) Nitrite [Presence] in Urine by Test strip

145

1320

1.18

0.74

5.2

4.5

0.00

estimate

0.50

259

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

194

1.37

0.74

1.5

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

1.57

0.73

1.5

1.6

—

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

261

2499

1.21

0.72

6.7

5.4

39.99

39.69

mmol/mol

0.20

243

2334

(3009261) Glucose [Presence] in Urine by Test strip

146

1334

1.17

0.70

4.0

3.4

0.00

estimate

0.00

250

(3013327) Hepatitis A virus IgM Ab [Presence] in Serum

1.72

0.70

1.0

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

1.72

0.70

1.0

1.5

—

(3017732) Neutrophils [#/volume] in Blood

170

1.38

0.69

3.3

2.6

3.12

3.83

e9/l

0.79

133

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

153

1.40

0.69

1.4

1.7

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

162

1.38

0.68

1.3

—

(3041096) Erythrocytes [Presence] in Urine by Automated

744

0.83

0.67

4.3

3.0

—

(3012336) Haptoglobin [Mass/volume] in Serum or Plasma

111

1.46

0.67

3.0

1.9

1.52

1.58

g/l

0.11

(44816844) Macroprolactin [Units/volume] in Serum or Plasma

1.80

0.66

3.8

1.4

—

(1616796) Gas panel - Central venous blood

1.63

0.66

3.1

2.3

—

(3024172) Erythropoietin (EPO) [Units/volume] in Serum or Plasma

1.60

0.65

1.1

1.2

214.31

14.48

u/l

—

(42868544) Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence

1.60

0.65

1.0

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

1.49

0.65

2.0

—

(3025023) Rhinovirus RNA [Presence] in Specimen by NAA with probe detection

1.73

0.64

1.6

1.7

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

522

1.21

0.62

1.5

1.8

238461941.31

445.56

pmol/l

0.49

437

(4094501)

1.61

0.62

1.1

—

(3010156) C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method

114

1.42

0.60

2.8

2.0

2.03

2.68

mg/l

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

264

0.74

0.60

1.8

1.7

—

(3006923) Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma

297

2895

1.27

0.59

14.2

9.9

26.14

26.56

u/l

0.17

291

2790

(3021440) Promyelocytes/100 leukocytes in Blood

203

1.30

0.57

4.1

4.2

0.00

0.18

—

(3037756) Immunofixation for Serum or Plasma

1.49

0.57

1.6

1.7

—

(3037121) Protein [Mass/volume] in Urine

1.45

0.57

5.4

3.3

0.19

0.20

g/l

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

1.68

0.57

1.3

1.4

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

1.46

0.56

5.9

3.1

—

(3000330) Specific gravity of Urine by Test strip

125

1.38

0.55

3.2

—

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

702

1.16

0.53

1.7

1.6

1.23

1.39

mmol/l

1.75

587

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

289

1.24

0.51

8.7

4.0

235.74

234.54

u/l

0.03

275

(3003694) ABO and Rh group [Type] in Blood

753

1.16

0.51

1.6

1.5

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

1.51

0.50

1.7

1.5

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

1.51

0.50

1.7

1.5

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

1.51

0.50

1.6

1.5

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

1.51

0.50

1.6

1.5

—

(3049717) Cytology report of Urine Cyto stain

1.41

0.49

1.8

2.8

—

(3006184) Hemoglobin [Mass/volume] in Capillary blood

1.49

0.47

2.3

2.0

123.60

131.11

g/l

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

1.47

0.47

1.4

1.5

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

0.60

0.46

1.4

1.5

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

263

2550

1.16

0.46

17.6

12.5

80.01

82.34

ml/min/173m2

0.88

224

2077

(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma

492

1.17

0.44

2.2

2.7

0.56

0.76

ug/l

2.22

305

(3013139) Helicobacter pylori Ag [Presence] in Stool

166

1.28

0.44

1.3

1.2

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

1.38

0.44

1.0

1.1

—

(3022806) Fractional oxyhemoglobin in Capillary blood

1.62

0.43

1.2

1.8

87.78

89.72

—

(3004616) Nuclear Ab [Presence] in Serum

1.62

0.43

1.2

—

(3020044) Glucose [Moles/volume] in Cerebral spinal fluid

1.44

0.43

1.1

1.3

3.59

3.71

mmol/l

—

(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection

1.57

0.42

1.6

1.7

—

(21494890) Protein electrophoresis panel - 24 hour Urine

1.57

0.42

1.6

2.6

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

194

0.76

0.41

1.4

—

(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

0.00

0.41

0.0

1.2

—

(42868414) European tick borne encephalitis virus IgM Ab [Presence] in Serum by Immunoassay

0.00

0.41

0.0

1.4

—

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

1.41

0.41

13.0

2.2

1863.82

831.26

ug/l

0.26

(3044242) Glucose [Moles/volume] in Arterial blood

0.00

0.41

0.0

1.7

—

(3007821) Glucose [Moles/volume] in Serum or Plasma --baseline

0.00

0.41

0.0

1.2

—

6.06

—

(3053028) Streptococcus sp identified in Specimen by Organism specific culture

0.00

0.41

0.0

1.3

—

(3017569) Oxygen content in Arterial blood

0.00

0.41

0.0

1.6

—

(1001509) Gas and Carbon monoxide and Electrolytes panel - Arterial blood

0.00

0.40

0.0

1.8

—

(3026470) Cobalt [Mass/volume] in Blood

0.00

0.40

0.0

2.1

—

3.63

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

0.40

0.0

2.1

—

(42868716) Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection

1.44

0.39

1.0

1.5

—

(3025468) Yersinia sp identified in Specimen by Organism specific culture

1.39

0.38

1.0

1.5

—

(3024522) Salmonella sp identified in Specimen by Organism specific culture

1.39

0.38

1.0

1.5

—

(3012568) Campylobacter sp identified in Specimen by Organism specific culture

1.39

0.38

1.0

1.5

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

423

1.16

0.38

1.3

1.2

9.72

9.01

u/ml

0.03

165

(3002523) Influenza virus A Ag [Presence] in Specimen

1.36

0.37

1.2

1.1

—

(3005988) Vibrio sp identified in Specimen by Organism specific culture

1.36

0.37

1.0

1.5

—

(3003740) Influenza virus B Ag [Presence] in Specimen

1.36

0.37

1.2

1.1

—

(3042631) Mycobacterium sp identified in Specimen

1.36

0.37

4.8

3.4

—

(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection

1.36

0.37

1.0

1.5

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

839

1.12

0.37

4.1

4.5

1.52

1.96

ug/l

2.28

753

(3025941) Bacteria identified in Stool by Culture

171

1.24

0.36

1.3

1.2

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

126

1.28

0.36

2.0

1.7

—

(21494755) Public health laboratory ask at order entry panel

282

0.84

0.31

1.1

1.3

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

1.34

0.30

1.8

1.6

—

(4034850)

1.30

0.30

7.4

9.2

—

(40760888) Immunoglobulin light chains.free panel - Serum

1.28

0.28

2.6

4.0

—

(3001019) Free T4 and TSH panel - Serum or Plasma

116

0.77

0.28

1.8

1.7

—

(1002224) Polysomnography panel

120

0.74

0.27

1.0

1.1

—

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

444

1.12

0.27

1.4

1.3

11.18

34.59

iu/ml

3.94

150

(3016921) Smith extractable nuclear Ab [Units/volume] in Serum

1.22

0.27

1.4

1.2

—

5.14

—

(3016888) Borrelia burgdorferi IgG Ab [Units/volume] in Serum

160

1.20

0.26

1.2

1.3

—

49.62

—

(40766189) Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay

1.21

0.25

1.0

—

9.84

—

(42868674) Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma

305

1.13

0.23

4.6

4.4

31.22

31.58

0.09

208

(3009804) Carcinoembryonic Ag [Mass/volume] in Pleural fluid

0.00

0.21

0.0

1.1

—

1.88

—

(3020650) Glucose [Presence] in Urine

0.00

0.21

0.0

1.5

—

(42868421) Varicella zoster virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay

0.00

0.21

0.0

1.2

—

(3044212) Herpes simplex virus 1+2 IgM Ab [Presence] in Cerebral spinal fluid

0.00

0.21

0.0

1.3

—

(3005411) Squamous cell carcinoma Ag [Mass/volume] in Serum or Plasma

0.00

0.21

0.0

2.3

—

2.76

—

(40761849) Varicella zoster virus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay

0.00

0.21

0.0

1.1

—

(3004451) EKG impression Narrative

0.00

0.21

0.0

1.5

—

(3030429) Borrelia sp DNA [Identifier] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.0

—

(3023024) Carbon dioxide [Partial pressure] in Capillary blood

166

0.84

0.21

8.3

3.6

5.19

5.10

kpa

0.20

158

(3044290) Cell count panel - Cerebral spinal fluid

1.25

0.20

1.2

1.4

—

(42868766) Dientamoeba fragilis DNA [Presence] in Stool by NAA with probe detection

0.00

0.20

0.0

1.2

—

(3008733) Herpes simplex virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

0.00

0.20

0.0

1.1

—

(3028707) Methadone [Presence] in Urine by Screen method

1.23

0.20

3.7

1.6

—

(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum

1.24

0.19

2.3

3.5

—

2.65

—

(3013512) EKG study

721

0.93

0.19

3.5

3.7

—

(3008230) Borrelia burgdorferi IgM Ab [Units/volume] in Serum

185

1.14

0.18

2.1

2.4

—

22.53

—

(3022313) Gas panel - Capillary blood

121

0.82

0.18

9.6

3.9

—

(3032836) C peptide [Moles/volume] in Serum or Plasma --fasting

1.19

0.18

10.7

1.3

0.95

0.93

nmol/l

—

(3005033) Fetal Nuchal fold Thickness US

1.15

0.17

1.6

1.5

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

1.15

0.17

1.7

1.5

—

(43534045) MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal

139

1.16

0.16

1.2

1.0

—

(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma

293

1.10

0.16

2.2

4.1

21.74

22.15

ug/l

0.01

246

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

599

1.06

0.14

1.4

1.2

0.43

1.09

u/ml

—

178

(3016879) Cocaine [Presence] in Urine

0.81

0.14

3.1

1.6

—

(3022621) pH of Urine by Test strip

170

1.12

0.14

1.5

2.3

—

(3028300) Cannabinoids [Presence] in Urine

106

0.84

0.13

2.9

1.6

—

(3000764) Benzodiazepines [Presence] in Urine

106

0.84

0.13

2.9

1.6

—

(3027008) Opiates [Presence] in Urine

106

0.84

0.13

2.9

1.6

—

(3027944) Amphetamines [Presence] in Urine

107

0.84

0.13

2.9

1.6

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

135

0.88

0.10

1.8

1.6

—

(3007164) IgA [Mass/volume] in Serum or Plasma

537

1.05

0.09

1.5

1.4

2.25

2.41

g/l

0.12

335

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

1.14

0.09

1.5

1.9

—

(40768797) Stomach Pathology biopsy report

351

1.06

0.09

1.2

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

0.83

0.08

1.0

1.8

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

1.10

0.08

1.7

1.6

—

(3022145) Colonoscopy Study observation

286

0.94

0.07

1.4

1.3

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

1.04

0.07

1.6

1.7

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

0.89

0.07

2.3

1.7

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

273

0.95

0.05

1.7

1.8

—

(40761536) Microorganisms panel - Urine sediment

241

0.95

0.04

6.0

3.3

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

411

0.97

0.03

1.4

—

(3020891) Body temperature

102

1.08

0.03

4.9

5.4

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

102

1030

0.99

0.02

4.5

3.4

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

259

1.00

0.00

1.4

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

301

1.00

0.00

1.8

1.9

—

(3029937) Albumin [Presence] in Urine by Test strip

734

0.99

0.00

5.1

3.6

0.00

estimate

0.50

257

(3043525) Herpes simplex virus Ab [Presence] in Cerebral spinal fluid

0.00

0.0

1.6

—

(40761539) Cells [Type] in Urine sediment by Light microscopy

0.00

0.0

1.1

—

(3022058) Hepatitis B virus DNA [Presence] in Serum or Plasma by NAA with probe detection

0.00

0.0

1.4

—

(3033888) Pepsinogen I [Mass/volume] in Serum or Plasma

0.00

0.0

1.4

—

76.88

—

(40758292) HTLV I+II Ab panel - Serum

0.00

0.0

1.8

—

(44806071)

0.00

0.0

1.1

—

(3015235) Bicarbonate [Moles/volume] in Capillary blood

0.94

0.00

3.0

2.3

22.95

24.91

mmol/l

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.91

0.00

1.2

1.3

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.99

0.00

1.3

1.6

—

(42868418) European tick borne encephalitis virus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay

0.00

0.0

1.4

—

(3002823) Mycoplasma pneumoniae IgG Ab [Units/volume] in Cerebral spinal fluid

0.00

0.0

1.0

—

(3011544) Albumin [Mass/volume] in Pleural fluid

0.00

0.0

1.0

—

15.12

—

(3041806) Other cells [#/volume] in Blood by Manual count

0.00

0.0

1.0

—

(3028334) Neisseria gonorrhoeae [Presence] in Specimen by Organism specific culture

0.00

0.0

1.6

—

(3037677) Mycoplasma pneumoniae IgM Ab [Titer] in Cerebral spinal fluid

0.00

0.0

1.1

—

(3029396) Erythrocyte agglutination [Presence] in Blood

0.00

0.0

1.6

—

(3014891) Appearance of Pleural fluid

0.00

0.0

1.2

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

0.96

0.00

2.0

1.9

—

(42868415) European tick borne encephalitis virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay

0.00

0.0

1.4

—

(42868417) European tick borne encephalitis virus IgG Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.4

—

(3037556) Urate [Mass/volume] in Serum or Plasma

0.00

0.0

1.4

—

(42529598) SUMO-activating enzyme subunit 1 Ab [Presence] in Serum by Line blot

0.00

0.0

1.0

—

(3009306) Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma

0.00

0.0

3.1

—

(42529582) MDA5 Ab [Presence] in Serum by Line blot

0.00

0.0

1.0

—

(42528593) TIF1-gamma Ab [Presence] in Serum by Line blot

0.00

0.0

1.0

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.91

0.00

1.2

1.7

—

(3003191) Choriogonadotropin (pregnancy test) [Presence] in Serum or Plasma

0.98

0.00

2.0

1.8

—

(3032057) Clostridioides difficile [Presence] in Stool

0.00

0.0

2.0

—

(3034988) Calcium [Moles/volume] in Capillary blood

0.00

0.0

2.1

—

1.17

—

(3034603) RHD gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal

0.00

0.0

1.7

—

(3027231) Wheat IgE Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(4133840)

0.00

0.0

1.0

—

(3014043) Spermatozoa Nonprogressive/100 spermatozoa in Semen

0.00

0.0

2.4

—

(3000213) Normetanephrine [Moles/time] in 24 hour Urine

0.00

0.0

1.4

—

2.14

—

(40758355) Pancreatic polypeptide [Moles/volume] in Serum or Plasma

0.00

0.0

4.8

—

60.30

—

(3043410) Blood group antigens tested for on Red Blood Cells

0.00

0.0

1.3

—

(37021550) Renin [Units/volume] in Plasma --upright

0.00

0.0

1.6

—

162.19

—

(3002619) Bacteria identified in Specimen by Culture

0.00

0.0

1.1

—

(3031072) Herpes simplex virus 1 IgG Ab [Presence] in Cerebral spinal fluid

0.00

0.0

1.0

—

(42868499) Enterovirus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay

0.00

0.0

1.1

—

(36306090) Helicobacter pylori [Presence] in Tissue by Organism specific culture

0.00

0.0

1.0

—

(3021901) Oxygen saturation in Capillary blood

1.00

0.00

3.8

2.2

—

(3030366) Cystatin C [Mass/volume] in Serum or Plasma

0.97

0.00

9.4

3.4

1.99

1.44

mg/l

—

(3010254) Herpes simplex virus identified in Specimen by Organism specific culture

0.00

0.0

1.0

—

(3011288) Drugs identified in Urine by Screen method

0.94

0.00

3.3

1.9

—

(37021073) Hepatitis C virus genotype in Serum or Plasma by Sequencing

0.00

0.0

1.0

—

(40761995) Spermatozoa Progressive [#/volume] in Semen

0.00

0.0

1.2

—

(3033386) Bacteria [Presence] in Cerebral spinal fluid by Light microscopy

0.00

0.0

1.4

—

(3029715) Chromosome analysis.interphase [Interpretation] in Bone marrow by FISH Narrative

0.00

0.0

1.6

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

0.98

0.00

1.2

1.1

—

(42869593) Oxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Capillary blood

0.00

0.0

1.4

—

(3018851) Theophylline [Moles/volume] in Serum or Plasma

0.00

0.0

1.5

—

40.00

—

(3004588) Protein electrophoresis panel - Serum or Plasma

180

1.00

0.00

1.7

2.2

—

(3042299) inFLIXimab [Mass/volume] in Serum or Plasma

0.00

0.0

4.1

—

6.34

—

(3035933) Granulocytes/100 leukocytes in Blood

0.00

0.0

1.0

—

(3013637) Mi-2 Ab [Presence] in Serum

0.00

0.0

1.0

—

(3039602) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Capillary blood

0.00

0.0

2.1

—

1.26

—

(3012741) Chlamydophila pneumoniae IgA Ab [Titer] in Serum

0.00

0.0

1.0

—

(3023365) Varicella zoster virus Ab [Titer] in Cerebral spinal fluid

0.00

0.0

1.3

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.95

0.00

3.1

1.5

—

(3043109) Cytology report of Tissue fine needle aspirate Cyto stain

0.94

0.00

1.0

1.3

—

(44806420)

0.00

0.0

2.5

—

(3007695) Herpes simplex virus 2 IgG Ab [Presence] in Cerebral spinal fluid

0.00

0.0

1.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint H7_CONJUNAS and mortality.

Females

Parameter	HR [95% CI]	p-value
H7_CONJUNAS	0.931 [0.7, 1.24]	0.623
Birth year	0.999 [0.99, 1.01]	0.831

During the follow-up period (1.1.1998 — 31.12.2019), 71 out of 895 females with H7_CONJUNAS died.

Males

Parameter	HR [95% CI]	p-value
H7_CONJUNAS	1.148 [0.85, 1.55]	0.366
Birth year	0.983 [0.97, 0.99]	< 0.001

During the follow-up period (1.1.1998 — 31.12.2019), 107 out of 871 males with H7_CONJUNAS died.

Mortality risk

Mortality risk for people of age

years, who have H7_CONJUNAS.

N-year risk	Females	Males
1	0.09%	0.194%
5	0.57%	1.137%
10	1.522%	2.871%
15	3.012%	5.649%
20	5.316%	9.392%

Relationships between endpoints

↥

Index endpoint: H7_CONJUNAS – Other specified and unspecified disorders of conjunctiva

GWS hits: 1

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Toxic effect of soaps and detergents

Drug-induced pemphigus

Palatinal maxillary operation

Necrobiosis lipoidica, not elsewhere classified

0 (0.00)

-0.20 [-1.01, 0.62]

Autoimmune diseases related-to ILD

41 (0.08)

Cytomegaloviral pneumonitis

-0.03 [-0.54, 0.48]

Malignant neoplasm of thymus

0 (0.00)

Other congenital malformations of digestive system

0 (0.00)

-0.68 [-1.79, 0.42]

Sclerosis of liver

Carcinoma in situ of middle ear and respiratory system

0 (0.00)

Assault by sharp object

0 (0.00)

Rapidly progressive nephritic syndrome

0 (0.00)

0.06 [-0.74, 0.86]

Infantile muscular atrophy

Biliary cirrhosis, secondary

Abnormal findings on diagnostic imaging of breast

Carcinoma in situ of skin of lip

0 (0.00)

Other and unspecified erythematous conditions

Traumatic amputation of forearm

Any mental disorder, or suicide (or attempt), or psychic disorders complicating pregnancy, partum or puerperum or nerve system disorders, excluding more controls

6 (0.04)

0.37 [-0.26, 1.00]

Gilbert syndrome

0 (0.00)

0.22 [-1.04, 1.49]

Hyperimmunoglobulin E [IgE] syndrome

0 (0.00)

ILD medications: prednisolone, methylprednisolone, prednisone

92 (0.10)

Failure of sterile precautions during surgical operation

0 (0.00)

Microcephaly

Carcinoma in situ of penis

Right hemicolectomy

Alcohol-induced pseudo-Cushing syndrome

Cardiomyopathies, Primary/intrinsic

Carcinoma in situ of skin, other sites/unspecified

0 (0.00)

Abnormality of red blood cells

0 (0.00)

Traumatic arthropathy

Mucopolysaccharidosis, type II

Myasthenia gravis

0.25 [-0.68, 1.19]

Drug-induced folate deficiency anaemia

Hypothermia

0 (0.00)

Use of donepezil

7 (0.08)

Benign neoplasm: Bone and articular cartilage, unspecified

0 (0.00)

-0.90 [-2.32, 0.53]

Other transepidermal elimination disorders

Oral lichen ruber planus

-0.11 [-1.02, 0.80]

Unspecified misadventure during surgical and medical care

Other congenital malformations of female genitalia

0 (0.00)

-1.00 [-3.54, 1.54]

Lesion of medial popliteal nerve

0.07 [-0.69, 0.83]

Tuberous sclerosis 1

0 (0.00)

Benzodiazepine use

42 (0.07)

Other overlap syndromes

0.13 [-0.58, 0.84]

Solar urticaria

0 (0.00)

Mucinous and mucinous cystic tumor

Porphyria cutanea tarda

0 (0.00)

Routine general health check-up of defined subpopulation

0 (0.00)

Other forms of systemic lupus erythematosus

-0.44 [-1.35, 0.47]

Hypertrophy of (infrapatellar) fat pad

0 (0.00)

-0.76 [-2.40, 0.88]

Benign neoplasm: Endocrine gland, other/unspecified

0 (0.00)

Used for control exclusion in common control thyroid runs

126 (0.08)

Beta thalassaemia

Pemphigus erythematosus

0 (0.00)

Carcinoma in situ of uteri, other/unspecified

0 (0.00)

Other specified/unspecified necrotizing vasculopathies

0 (0.00)

-1.00 [-3.06, 1.06]

Benign neoplasm: Appendix

0 (0.00)

Other accidental hanging and strangulation

0 (0.00)

Hereditary motor and sensory neuropathy

0 (0.00)

-0.27 [-1.47, 0.94]

Hereditary factor XI deficiency

Myelofibrosis

Other specified air transport accidents

Encephalocele

Hodgkin lymphoma

0 (0.00)

-0.53 [-1.97, 0.91]

Lymphocyte function antigen-1 [LFA-1] defect

Abnormal findings in secretions and smears from cervix uteri vagina vulva

Calcific aortic valvular stenosis, diagnosis (helper)

8 (0.06)

Subacute thyrotoxicosis, drug-induced

Congenital malformation of biliary tract

0 (0.00)

0.45 [-0.53, 1.42]

L02BG Aromatase inhibitors

11 (0.09)

Habitual aborter

-0.04 [-3.22, 3.14]

Congenital malformations of pulmonary and tricuspid valves

-0.49 [-1.91, 0.93]

Thyrotoxicosis factitia

0 (0.00)

0.12 [-0.58, 0.83]

Nutritional anaemias

15 (0.06)

Listeriosis

-0.66 [-1.72, 0.40]

Congenital and developmental myasthenia

0 (0.00)

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified (FINNGEN)

53 (0.09)

Hereditary angioödema type 1

0 (0.00)

Retinoblastoma

0 (0.00)

Melanoma in situ of upper limb, including shoulder

0 (0.00)

Asthma (only as main-diagnosis), excluding more controls

50 (0.10)

-0.04 [-0.36, 0.29]

Other and specified injuries of hip and thigh

0 (0.00)

Open wounds involving multiple body regions

Lung cancer and mesothelioma

6 (0.06)

Recurrent and persistent haematuria

0 (0.00)

0.33 [-0.58, 1.24]

Periodontal disease, other/unspecified

0 (0.00)

Congenital malformations of posterior segment of eye

-0.44 [-1.39, 0.51]

Testicular dysfunction, other/unspecified

0.59 [-0.73, 1.91]

Cryoglobulinemia

0 (0.00)

0.40 [-0.37, 1.18]

Other and unspecified disorders of adult personality and behaviour

-0.03 [-0.87, 0.81]

Vascular dementia (multiple infarctions)

0 (0.00)

-0.24 [-1.34, 0.85]

Other systemic involvement of connective tissue

Malignant neoplasm of respiratory system and intrathoracic organs

5 (0.05)

Lumbar disc prolapse

25 (0.07)

-0.01 [-0.35, 0.33]

Phlebitis and thrombophlebitis of lower extremities, unspecified, drug-induced

-0.04 [-1.36, 1.27]

Carcinoma in situ of cervix uteri, exocervix

0 (0.00)

UC patients in KELA-register (code 208), prior to 1994

Vascular dementia (mixed)

-0.41 [-1.58, 0.75]

Benign neoplasm: Short bones of upper limb

0 (0.00)

Other specific arthropathies, wide

0 (0.00)

0.91 [-0.76, 2.57]

Idiopathic peripheral autonomic neuropathy

-0.20 [-1.12, 0.71]

Injury, poisoning and certain other consequences of external causes

225 (0.07)

Use of melevodopa decarboxylase inhibitor

Hypotension due to drugs

0 (0.00)

0.07 [-0.87, 1.01]

Other ill-defined and unspecified causes of mortality

Carcinoma in situ of vulva

Fracture of lower limb, level unspecified

Melanoma in situ of other and unspecified parts of face

Toxic effects of substances chiefly nonmedicinal as to source

Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers)

6 (0.06)

-0.25 [-0.89, 0.38]

Bartonellosis

0 (0.00)

Injury of blood vessels at hip and thigh level

0 (0.00)

Ovarian dysfunction: estrogen excess, drug-induced

Iodine-deficiency-related thyroid disorders and allied conditions

0 (0.00)

Disorders of puberty, other/unspecified

0 (0.00)

0.19 [-0.59, 0.97]

Inflammatory disorders of male genital organs, not elsewhere classified

0 (0.00)

0.11 [-1.08, 1.30]

Endometroid carcinoma of ovary

0 (0.00)

Other and unspecified diseases of spleen

0 (0.00)

-0.06 [-1.02, 0.90]

Combined immunodeficiencies

0.36 [-0.70, 1.43]

Malignant melanoma, excluding all cancers (controls excluding all cancers)

6 (0.08)

-0.27 [-0.87, 0.33]

Explicit viral Sepsis

0 (0.00)

Methotrexate

Use of levodopa

Other bursitis of knee

0 (0.00)

-0.68 [-2.37, 1.02]

Disorder of pancreatic internal secretion, other and/or unspecified

0.82 [-0.62, 2.25]

Unspecified behavioural syndromes associated with physiological disturbances and physical factors +Physiological and behavioural factors associated with disorders of diseases classified elsewhere

0 (0.00)

0.39 [-0.63, 1.41]

Malignant neoplasm of head and neck, excluding all cancers (controls excluding all cancers)

6 (0.14)

-0.10 [-1.03, 0.83]

Dementia in other diseases classified elsewhere

0 (0.00)

Benign neoplasm: Other/unspecified site

0 (0.00)

Perioral dermatitis, drug-induced

0 (0.00)

Parodontitis, under 40 years and operation codes

0 (0.00)

Gender identity disorders

0 (0.00)

-0.51 [-1.49, 0.48]

Benign neoplasm: Epididymis

0 (0.00)

Other hereditary haemolytic anaemias

Malignant neoplasm of eye and adnexa, excluding all cancers (controls excluding all cancers)

10 (1.13)

-0.36 [-1.35, 0.63]

Labyrinthine fistula

0 (0.00)

0.18 [-0.48, 0.85]

Dental pulpitis 3, only avohilmo

Other deformity of hallux (acquired)

0.44 [-0.71, 1.59]

Injury of muscle and tendon at shoulder and upper arm level

16 (0.10)

Benign neoplasm: Aortic body and other paraganglia

Problems related to life-management difficulty

8 (0.13)

Use of apomorphine

Benign neoplasm: Ribs, sternum and clavicle

0 (0.00)

Benign neoplasm of bone and articular cartilage

Functional disorders of polymorphonuclear neutrophils

Benign intracranial hypertension

0 (0.00)

0.47 [-0.74, 1.67]

Perioral dermatitis

0.54 [-0.71, 1.79]

Other cestode infections

0 (0.00)

0.08 [-0.62, 0.77]

Malignant neoplasm of oesophagus

0 (0.00)

Echinococcosis

Carcinoma in situ of rectum

Carcinoma in situ of breast, intraductal

-0.16 [-0.84, 0.52]

Other sex chromosome abnormalities, female phenotype, not elsewhere classified

Adjustment and management of implanted device

7 (0.09)

Adenocarcinoma of pancreas

0 (0.00)

Other helminthiases

0 (0.00)

Thromboangiitis obliterans

0 (0.00)

0.13 [-0.67, 0.93]

Malignant neoplasm of other and ill-defined sites, excluding all cancers (controls excluding all cancers)

Malignant neoplasm, without specification of site

Benign neoplasm: Long bones of lower limb

-0.54 [-2.55, 1.48]

Benign neoplasm: Mediastinum

0 (0.00)

-0.14 [-0.97, 0.69]

Benign lipomatous neoplasm of intrathoracic organs

0 (0.00)

Benign neoplasm: Extrahepatic bile ducts

0 (0.00)

-0.11 [-0.86, 0.63]

Burns and corrosions of external body surface, specified by site

Crystalline deposits in vitreous body

0 (0.00)

-0.29 [-1.19, 0.61]

Squamous cell neoplasms and carcinoma of cervix, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.60 [-0.68, 1.88]

Unspecified hairloss

0 (0.00)

Pathological/recurrent dislocation and subluxation of joint, not elsewhere classified

6 (0.15)

Venous complications and haemorrhoids in the puerperium

0 (0.00)

-0.38 [-1.45, 0.68]

Other heart diseases, wide

111 (0.09)

Other infiltrative disorders of skin and subcutaneous tissue

-0.47 [-1.59, 0.66]

Yellow fever

Poisoning by narcotics and psychodysleptics [hallucinogens]

Other and unspecified haemorrhagic conditions

0 (0.00)

-0.38 [-2.16, 1.40]

Combinations of oral blood glucose lowering drugs

9 (0.07)

Viral hepatitis, IBD co-morbidity

Selective serotonin reuptake inhibitors

62 (0.06)

Calculus of urinary tract in diseases classified elsewhere

Streptococcus and staphylococcus as the cause of diseases classified to other chapters

0 (0.00)

0.20 [-0.78, 1.18]

Superficial injuries involving multiple body regions

L01XE Protein kinase inhibitors

Kernicterus

0 (0.00)

Malignant neoplasm of liver and intrahepatic bile ducts

0 (0.00)

TMD related operations

5 (0.07)

0 (0.00)

-0.31 [-1.20, 0.57]

Acquired absence of limb

Congenital malformations of great arteries

-0.42 [-1.52, 0.67]

Communicating hydrocephalus

0.26 [-0.64, 1.16]

Brain astrocytoma

0 (0.00)

Persons encountering health services for specific procedures and health care

89 (0.11)

Other inflammatory disorders of orbit (ICD-8 only)

Indeterminate sex and pseudohermaphroditism

Other nutritional deficiencies

33 (0.09)

Von Hippel-Lindau syndrome

Disorders of lens

97 (0.10)

Unspecified multiple injuries

Discharge of firework

Leiomyosarcoma

0 (0.00)

Colitis, primary sclerosing, strict definition

0.04 [-0.63, 0.71]

Other orthopaedic follow-up care

Disorders of multiple cranial nerves

Murder, homicide, or other assault by rifle, shotgun and larger firearm discharge

0 (0.00)

Osteopathy in diseases classified elsewhere

-0.55 [-1.82, 0.72]

Failed attempted abortion

0 (0.00)

0.84 [-1.35, 3.03]

Other disorders of middle ear and mastoid in diseases classified elsewhere

Motor disorders, excluding more controls

0 (0.00)

-0.08 [-1.08, 0.92]

Left bundle-branch block

0 (0.00)

-0.34 [-1.22, 0.54]

Abscess of tendon sheath

-1.00 [-2.77, 0.77]

Polycythaemia vera

-0.08 [-0.73, 0.57]

Other melanin hyperpigmentation

0.80 [-0.79, 2.38]

Lichenoid drug reaction

0 (0.00)

0.39 [-0.49, 1.28]

Congenital glaucoma

0 (0.00)

Spinal instabilities

0.35 [-0.72, 1.43]

Benign neoplasm: Lymph nodes

0 (0.00)

0.24 [-0.59, 1.07]

Cerebral arteritis

0 (0.00)

0.44 [-0.51, 1.40]

Tumor necrosis factor alpha inhibitors

6 (0.09)

Exposure to unspecified factor

33 (0.06)

Other fibroblastic disorders

0 (0.00)

-0.07 [-0.78, 0.64]

Familial chondrocalcinosis

Other and unspecified degenerative diseases of nervous system

-0.85 [-2.60, 0.89]

Occupant of heavy transport vehicle injured in other and unspecified transport accidents

0 (0.00)

Toxic erythema

0 (0.00)

0.17 [-0.45, 0.80]

Carcinoma in situ of skin of lower limb, including hip

Dislocation, sprain and strain of joints and ligaments of shoulder girdle

9 (0.06)

Malignant neoplasm of rectosigmoid junction, excluding all cancers (controls excluding all cancers)

Superficial injury of forearm

6 (0.13)

Other and unspecified diseases of blood and blood-forming organs

0 (0.00)

0.59 [-0.71, 1.88]

Other articular cartilage disorders

0.25 [-1.47, 1.97]

Adrenogenital disorders

0 (0.00)

0.68 [-0.52, 1.89]

Mucopolysaccharidosis, other/unspecified

0 (0.00)

Etanercept

Benign neoplasm of mesothelial tissue

Carcinoma in situ of skin of other and unspecified parts of face

Disorders of glycosaminoglycan metabolism

0 (0.00)

Traumatic secondary and recurrent haemorrhage

0 (0.00)

Other and unspecified cicatricial alopecia

0 (0.00)

-0.41 [-1.29, 0.47]

Melanocytic naevi

13 (0.09)

Exclusions for E4_PCOS_CONSORTIUM

36 (0.06)

Amputation of toe

Obstetric and gynaecological devices associated with adverse incidents

Cholangitis (primary sclerosing, PSC), with reimbursement 202

0 (0.00)

-0.56 [-1.59, 0.47]

Abscess of lung

-0.19 [-1.35, 0.96]

Syphilis

1.00 [-1.56, 3.56]

Injury of blood vessels at wrist and hand level

0 (0.00)

Traumatic amputation of part of head

0 (0.00)

Malignant neoplasm of other and unspecified urinary organs, excluding all cancers (controls excluding all cancers)

0 (0.00)

Other rickettsioses

Other (not insulin) diabetes medications

64 (0.08)

Crohn disease (strict definition, require KELA)

Meningococcal infection

0 (0.00)

0.91 [-1.17, 2.98]

Non-follicular lymphoma, hilmo, excluding all cancers

6 (0.15)

-0.35 [-1.22, 0.52]

Poisoning by and exposure to other and unspecified chemicals and noxious substances, undetermined intent

Iridocyclitis in diseases classified elsewhere

0.43 [-0.52, 1.39]

Linear scleroderma

0 (0.00)

Other assisted single delivery

0 (0.00)

0.71 [-1.51, 2.93]

Polydactyly

Assault by blunt object

Pedestrian injured in collision with other nonmotor vehicle

Injury of blood vessels at ankle and foot level

Disorder of carbohydrate metabolism, other/unspecified

0 (0.00)

-0.00 [-0.64, 0.63]

Common variable immunodeficiency with autoantibodies to B- or T-cells

0 (0.00)

Substance abuse, excluding more controls

20 (0.06)

0.30 [-0.21, 0.81]

Neonatal jaundice due to drugs or toxins transmitted from mother or given to newborn

Pseudosarcomatous fibromatosis

0 (0.00)

Benign neoplasm of colon, rectum, anus and anal canal

26 (0.09)

Unspecified pneumoconiosis

Unspecified parasitic disease

0 (0.00)

0.33 [-0.94, 1.61]

Carcinoma in situ of endometrium

-0.07 [-0.79, 0.66]

Soft tissue disorders in diseases classified elsewhere

0 (0.00)

Colitis due to radiation

Congenital malformation of vitreous humour

Benign neoplasm: Carotid body

0 (0.00)

0.06 [-0.74, 0.85]

Sphingolipidosis, other/unspecified

0 (0.00)

Chromium deficiency

Epileptic seizures related to alcohol

0 (0.00)

-0.39 [-1.36, 0.58]

Carcinoid syndrome

0 (0.00)

0.04 [-1.23, 1.31]

Pedestrian injured in other and unspecified transport accidents

0 (0.00)

Eosinophilia

Defects in the complement system

0 (0.00)

0.04 [-0.99, 1.08]

Ependymoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.01 [-0.58, 0.56]

Dysplastic lesion of the vulva of unknown severity

0.29 [-0.38, 0.96]

Mastocytosis

0 (0.00)

-0.14 [-1.36, 1.09]

Portal vein thrombosis

0 (0.00)

0.74 [-0.58, 2.06]

Sunburn

0 (0.00)

-0.15 [-0.80, 0.49]

Wrist or foot drop (acquired)

0 (0.00)

Acetic acid derivatives and related substances

93 (0.08)

Traumatic spondylopathy

0 (0.00)

0.47 [-0.43, 1.36]

Open wound of shoulder and upper arm

Autonomic dysreflexia

Benign neoplasm: Central nervous system, other parts/unspecified

0 (0.00)

Dental pulpitis 2, only avohilmo

186 (0.07)

Exposure to high-pressure jet

Profound mental retardation

Colon adenocarcinoma, excluding all cancers (controls excluding all cancers)

0.40 [-0.55, 1.35]

Benign neoplasm of eye and adnexa

33 (0.80)

Benign neoplasm: Vertebral column

0 (0.00)

Other symptoms and signs involving the digestive system and abdomen

6 (0.08)

Systemic lupus erythematosus

Malignant neoplasm of penis

Benign neoplasm: Heart

0 (0.00)

Psoas tendinitis

0 (0.00)

-0.95 [-2.49, 0.60]

Hyperkinetic disorders, excluding more controls

6 (0.11)

0.06 [-0.60, 0.73]

Cleft lip

0 (0.00)

-0.44 [-1.36, 0.48]

Other disorders of bone development and growth

0 (0.00)

Conductive and sensorineural hearing loss

40 (0.08)

Use of trihexyphenidyl

18 (0.05)

Care involving dialysis

9 (0.27)

Benign neoplasm of other and ill-defined parts of digestive system

7 (0.09)

Use of dimethyl fumarate

0 (0.00)

Other and unspecified injuries of lower leg

ILD medications: immunosuppressive drugs

39 (0.11)

Pedal cyclist injured in collision with train or tram

Ophthalmic devices associated with adverse incidents

Respiratory conditions due to other external agents

-0.46 [-2.26, 1.34]

Inflammation of lacrimal passages (acute and unspecified)

0 (0.00)

-0.01 [-1.09, 1.08]

Other symptoms and signs involving general sensations and perceptions

Acute otitis externa, noninfective

0 (0.00)

0.03 [-1.14, 1.20]

Disorders of muscle in diseases classified elsewhere

Chronic crepitant synovitis/bursitis of hand and wrist/periarthritis of wrist

-0.85 [-2.31, 0.61]

Disorders of glycine metabolism

Other disorders of electrolyte and fluid balance, not elsewhere classified

0 (0.00)

Clefts and syndromes for tooth agenesis exclusion, including avohilmo

Pemphigus vulgaris

0 (0.00)

0.15 [-0.63, 0.93]

Drug-induced autoimmune haemolytic anaemia

Poikiloderma of Civatte

0 (0.00)

-0.23 [-0.94, 0.49]

Sequelae of injuries of neck and trunk

Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)

94 (0.07)

Melanocytic naevi of lip

0 (0.00)

Otitis media in diseases classified elsewhere

0 (0.00)

Other acantholytic disorders

0.04 [-0.69, 0.76]

Toxic myoneural disorders

Early syphilis

0.72 [-0.81, 2.25]

Birth trauma

0 (0.00)

-0.03 [-1.60, 1.53]

Short stature, not elsewhere classified

0 (0.00)

Disease of hard tissues of teeth, NOS

Chronic myeloid leukaemia

Use of eye-antiallergens (taken as indicator of allergic/atopic conjunctivitis)

43 (0.14)

Rheumatic valve diseases

-0.16 [-1.62, 1.30]

Gluteal tendinitis

0 (0.00)

-0.42 [-1.63, 0.79]

Other and unspecified water transport accidents

0 (0.00)

-0.12 [-0.91, 0.68]

Neglect and abandonment

Inguinal of femoral hernia, unilateral

0 (0.00)

Kaposi sarcoma, excluding all cancers (controls excluding all cancers)

-0.45 [-1.27, 0.37]

Malignant neoplasm of other and unspecified parts of biliary tract, excluding all cancers (controls excluding all cancers)

0 (0.00)

Any gastric operation

173 (0.08)

Oher contracture of tendon (sheath)

0 (0.00)

-0.19 [-0.94, 0.57]

Open bite that required surgery (Lefort1 or BSSRO)

0 (0.00)

1.00 [-0.71, 2.71]

Duodenal ulcer - Acute with haemorrhage, drug-induced

0.24 [-0.46, 0.94]

Narcolepsy and cataplexy

0 (0.00)

-0.19 [-1.15, 0.78]

Abnormal findings on diagnostic imaging and in function studies, without diagnosis

26 (0.08)

Ependymoma

0 (0.00)

Peripheral arterial reconstruction

6 (0.08)

Malignant cancer of tonsil and base of tongue, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.01 [-1.77, 1.80]

Injury of muscle and tendon at wrist and hand level

Abnormal findings in nipple discharge synovial fluid wound secretions

0 (0.00)

Injury of muscle and tendon at lower leg level

Benign neoplasm: Bone and articular cartilage, unspecified

0 (0.00)

Conditions involving the integument and temperature regulation of fetus and newborn

0 (0.00)

African trypanosomiasis

Disorders of other visual pathways

Other leukaemias of specified cell type

0 (0.00)

Injury of blood vessels at abdomen, lower back and pelvis level

0 (0.00)

Secondary malignant neoplasm of other and unspecified sites

0 (0.00)

Dialysis, with operation codes

13 (0.24)

Disorders of peritoneum in infectious diseases classified elsewhere

Other hyperalimentation

0 (0.00)

-0.02 [-0.69, 0.65]

Fasciculation

Urticaria due to cold and heat

0.91 [-0.75, 2.57]

Failure in dosage during surgical and medical care

Irritant contact dermatitis due to drugs in contact with skin

Collagenous colitis

Benign neoplasm: Pineal gland

Malignant neoplasm of digestive organs

6 (0.03)

Neuroendocrine tumor and carcinoma of small intestine

0 (0.00)

Hyperinsulinism NOS, drug-induced

Carcinoma in situ of lip, oral cavity and pharynx

0 (0.00)

Follicular adenocarcinoma of thyroid gland

0 (0.00)

Benign neoplasm: Bladder

0 (0.00)

Procedures for purposes other than remedying health state

Benign neoplasm: Connective and other soft tissue of head, face and neck

Other congenital malformations of circulatory system

0.15 [-1.32, 1.62]

Benign neoplasm: Pluriglandular involvement

Dengue fever [classical dengue]

0.20 [-0.45, 0.85]

Malignant neoplasm of oral cavity, excluding all cancers (controls excluding all cancers)

0.10 [-1.10, 1.30]

Injury of muscle and tendon at neck level

0 (0.00)

Disorder of visual pathways, unspecified

0 (0.00)

0.42 [-0.33, 1.17]

Benign neoplasm: Renal pelvis

0 (0.00)

0.16 [-0.47, 0.80]

Unspecified privation

Other and unspecified hypertrophic disorders of skin

-0.26 [-1.41, 0.90]

Dermatopolymyositis (FG)

0 (0.00)

0.19 [-0.74, 1.12]

Retained (old) foreign body following penetrating wound of orbit

0 (0.00)

Burn and corrosion, body region unspecified

0 (0.00)

Other and unspecified syphilis

0.36 [-0.51, 1.24]

Carcinoma in situ, bladder

0 (0.00)

Late syphilis

0.35 [-0.70, 1.41]

Unspecified protein-energy malnutrition

0.09 [-0.87, 1.06]

Panniculitis, unspecified

0.52 [-0.71, 1.76]

Problems related to education and literacy

0 (0.00)

Other and unspecified disorders of pigmentation

0 (0.00)

0.43 [-0.69, 1.54]

Disorders of conjunctiva

329 (0.70)

Other degenerative disorders of globe

0 (0.00)

L01XA Platinum compounds

Diving or jumping into water causing injury other than drowning or submersion

0 (0.00)

Adult respiratory distress syndrome

0 (0.00)

0.08 [-0.75, 0.91]

Photocontact dermatitis [berloque dermatitis]

0 (0.00)

Motor- or nonmotor-vehicle accident in traffic area

Dislocation, sprain and strain of joints and ligaments of elbow

Acute alcohol intoxication ICD-9

0 (0.00)

Fungal Sepsis

Ulcerative colitis (strict definition, require KELA)

Abnormal results of function studies

Strabismus

23 (0.18)

Complications following myocardial infarction

0.62 [-1.07, 2.32]

Injuries to the hip and thigh

19 (0.08)

Exposure to uncontrolled fire, not in building or structure

0 (0.00)

Viral infections of central nervous system, not elsewhere classified/unspecified

Acquired epidermolysis bullosa

Mucinosis of skin

0 (0.00)

Congenital malformations of ear causing impairment of hearing

0.23 [-0.61, 1.06]

In situ neoplasms

16 (0.09)

Certain conditions originating in the perinatal period

Pacemaker

17 (0.12)

Disease of thymus, other/unspecified

0 (0.00)

-0.22 [-0.85, 0.42]

Dermatitis herpetiformis

-0.02 [-0.53, 0.50]

Dislocation, sprain and strain of joints and ligaments at wrist and hand level

13 (0.09)

Complications of anaesthesia during labour and delivery

0 (0.00)

0.14 [-0.62, 0.91]

Benign neoplasm: Cranial nerves

0 (0.00)

Inhalation of gastric contents

Other and unspecified vasculitis limited to skin

0 (0.00)

-0.31 [-1.26, 0.65]

Kissing spine

0 (0.00)

-0.06 [-0.62, 0.50]

Neurological diseases

168 (0.08)

Hypopituitarism after medical therapy

Endometriosis of intestine

0.40 [-0.75, 1.55]

Dental caries 1, only avohilmo

163 (0.07)

Necrotizing enterocolitis of fetus and newborn

Disorders of amino-acid transport

0 (0.00)

-0.10 [-0.60, 0.39]

Abscess of spleen

Arthropathy in ulcerative colitis

-0.07 [-0.80, 0.66]

Complications of surgical and medical care, not elsewhere classified

48 (0.08)

Other transitory neonatal endocrine disorders

0 (0.00)

Use of tropatepine

Airway disease due to specific organic dust

0 (0.00)

-0.30 [-1.01, 0.41]

Traumatic subcutaneous emphysema

Specific personality disorders

Benign neoplasm: Colon

22 (0.09)

Carcinoma in situ of uteri, other/unspecified

0 (0.00)

Demyelinating diseases of the central nervous system

Disorders of porphyrin and bilirubin metabolism

0 (0.00)

-0.00 [-0.78, 0.77]

Brain astrocytoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.22 [-0.72, 1.16]

Other congenital malformations of limb(s)

-0.07 [-1.55, 1.41]

Other benign neoplasm of uterus: Corpus uteri

0 (0.00)

DVT of lower extremities and pulmonary embolism

16 (0.08)

Other and unspecified thalassaemias

Malignant neoplasm of prostate, excluding all cancers (controls excluding all cancers)

7 (0.03)

0.17 [-0.30, 0.64]

116

Livedoid vasculitis

0 (0.00)

0.65 [-0.43, 1.74]

Hip and thigh

0 (0.00)

Melanoma in situ of ear and external auricular canal

Parodontitis

31 (0.06)

Malignant neoplasm of other and unspecified female genital organs

0 (0.00)

Other and unspecified primary disorders of muscles

0 (0.00)

0.02 [-1.14, 1.19]

Benign neoplasm: Tonsil

0 (0.00)

-0.29 [-1.26, 0.69]

Use of tolcapone

0 (0.00)

Carcinoma in situ of oesophagus

Exposure to other and unspecified inanimate mechanical forces

Ethmoidectomy

6 (0.10)

Benign neoplasm: Bones of skull and face

0 (0.00)

-0.67 [-2.05, 0.70]

Benign neoplasm: Connective and other soft tissue of thorax

0 (0.00)

Foreign body or object entering through skin

Behçet disease

0 (0.00)

-0.34 [-1.13, 0.46]

Sequelae of complication of pregnancy, childbirth and the puerperium

Foreign object accidentally left in body during surgical and medical care

0 (0.00)

Respiratory tuberculosis, confirmed and not-confirmed

Unspecified visual impairment (binocular)

0 (0.00)

ILD medications: pirfenidone

0 (0.00)

Fat embolism (traumatic)

0 (0.00)

Other operation for atrial fibrillation

0 (0.00)

Other specified disorders of skin and subcutaneous tissue in diseases classified elsewhere

Hirsprung

0 (0.00)

Convalescence

Complications of anaesthesia during the puerperium

0 (0.00)

-0.13 [-0.99, 0.73]

Acute disseminated encephalitis/encephalomyelitis, drug-induced

Postdysenteric arthropathy

-0.97 [-2.75, 0.81]

Certain infectious and parasitic diseases

132 (0.08)

Extracorporeal dialysis

9 (0.36)

Bilateral visual impairment (ICD-8)

Ectopic hormone secretion, not elsewhere classified

0 (0.00)

Habit and impulse disorders

0.02 [-0.86, 0.89]

Unspecified jaundice

Other behavioural and emotional disorders with onset usually occurring in childhood and adolescence

0 (0.00)

Malignant neoplasm of anus and anal canal, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.44 [-0.68, 1.56]

Onychogryphosis

0 (0.00)

-0.78 [-2.19, 0.63]

Open wound of neck

Calcific aortic valvular stenosis

8 (0.06)

Pemphigus foliaceus

Inguinal or femoral hernia, bilateral

Malignant neoplasm of palate, excluding all cancers (controls excluding all cancers)

0 (0.00)

Benign neoplasm: Pluriglandular involvement

Testicular dysfunction

Genitourinary diseases

218 (0.07)

Family history of other specific disorders

Abnormal pulmonary venous return

0 (0.00)

0.40 [-0.32, 1.11]

Megavitamin-B6 syndrome

Family history of tobacco abuse

Dermatopolymyositis, unspecified

0 (0.00)

-0.16 [-1.08, 0.75]

Spotted fever [tick-borne rickettsioses]

Benign neoplasm: Scrotum

0 (0.00)

0.05 [-0.68, 0.78]

Neuronal ceroid lipofuscinosis

Copper deficiency

0 (0.00)

Mature T/NK-cell lymphomas, hilmo

0 (0.00)

Cardiomyopathy due to drugs and other external agents

0.03 [-0.51, 0.56]

Cushing syndrome

-0.93 [-2.76, 0.90]

Use of biperiden

Malignant neoplasms of independent (primary) multiple sites

Burkitt lymphoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

Marfan's syndrome

0 (0.00)

0.27 [-0.66, 1.20]

Calcaneal spur

0 (0.00)

0.43 [-1.09, 1.96]

Rifle, shotgun and larger firearm discharge, undetermined intent

Hypertrophic cardiomyopathy

0 (0.00)

-0.41 [-1.45, 0.63]

Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.20 [-1.30, 0.91]

Monoamine oxidase A inhibitors

N06DA Anticholinesterases

12 (0.08)

Wilms' tumor

0 (0.00)

-0.00 [-0.80, 0.80]

Persons encountering health services in other circumstances, wide

80 (0.08)

Glaucoma secondary to other eye disorders

Mental and behavioural disorders due to tobacco

General- and plastic-surgery devices associated with adverse incidents

0 (0.00)

Other benign neoplasm of uterus: Cervix uteri

0 (0.00)

Other endophthalmitis

0 (0.00)

-0.24 [-1.10, 0.62]

Intentional self-harm by explosive material

Other and unspecified vascular occlusions

Enterobiasis

0 (0.00)

-0.44 [-1.43, 0.55]

Constitutional tall stature

0 (0.00)

Kaposi sarcoma

ILD, hospital admissions

7 (0.11)

Benign neoplasm: Extrahepatic bile ducts

0 (0.00)

Burns and corrosions

5 (0.08)

Nosocomial condition (hospital)

0 (0.00)

Motor neuron disease

0 (0.00)

-0.30 [-1.57, 0.97]

Use of natalizumab

Lethal midline granuloma

Colectomy operation

7 (0.10)

Use of etilevodopa decarboxylase inhibitor

Phakomatoses, not elsewhere classified

Lack of expected normal physiological development

0 (0.00)

Fibrosis and sclerosis of liver

0 (0.00)

Congenital malformations of trachea and bronchus

0 (0.00)

-0.74 [-2.16, 0.68]

Protrusioacetabuli

Necrotizing fasciitis

0 (0.00)

-0.51 [-1.50, 0.47]

Complications of anaesthesia during pregnancy

0 (0.00)

-0.62 [-1.68, 0.44]

Chronic thyroiditis

0.29 [-0.54, 1.13]

Benign neoplasm: Endocrine pancreas

0 (0.00)

GI-bleeding

7 (0.05)

Other specified acquired deformities of limbs

0 (0.00)

0.60 [-0.48, 1.67]

Nocardiosis

Interstitial emphysema and related conditions originating in the perinatal period

0.33 [-0.38, 1.05]

Drug phototoxic response

0 (0.00)

Other/unspecified mastoiditis and related conditions

0 (0.00)

-0.15 [-1.41, 1.11]

Benign neoplasm: Skin of lip

0 (0.00)

Other abnormalities of plasma proteins

0 (0.00)

Melanoma of uvea

0 (0.00)

0.03 [-0.91, 0.96]

Persons encountering health services for examination and investigation

211 (0.08)

Frontotemporal dementia, wide, incl. Pick's disease

0 (0.00)

Dependence on enabling machines and devices, not elsewhere classified

Other and unspecified acute skin changes due to ultraviolet radiation

0 (0.00)

Acute hepatitis A

0.76 [-0.57, 2.10]

Hypersecretion of calcitonin

Unspecified fall

25 (0.10)

Benign neoplasm: Liver/bile ducts

0 (0.00)

Gangrene, not elsewhere classified

0 (0.00)

Type 2 diabetes

70 (0.07)

Melanoma in situ, other sites/unspecified

0 (0.00)

Persons encountering health services in circumstances related to reproduction

54 (0.05)

Diagnoses used for exclusion with ILD

14 (0.12)

Diastrofic dysplasy

Duodenal ulcer - Unspecified as acute or chronic, without haemorrhage or perforation, drug-induced

0 (0.00)

-0.17 [-0.99, 0.66]

Acquired keratosis follicularis

0 (0.00)

Drug-induced myopathy

0 (0.00)

-0.41 [-1.28, 0.47]

Use of cabergoline

Enteropathic arthropathies

-0.01 [-0.70, 0.68]

Other disorders originating in the perinatal period

0 (0.00)

0.21 [-0.77, 1.20]

Benign neoplasm: Connective and other soft tissue, unspecified

0 (0.00)

Combined immunodeficiency, unspecified

0 (0.00)

Other and unspecified firearm discharge, undetermined intent

Folliculitis ulerythematosa abscedens

Relapsing panniculitis [Weber-Christian]

Melanoma in situ of scalp and neck

0 (0.00)

Iliac crest spur

0 (0.00)

Scleritis and episcleritis

15 (0.56)

Other CVD (FINNGEN)

Drug-induced fever

0 (0.00)

Gangrene and necrosis of lung

Other inherited muscular atrophy

0 (0.00)

Injury of intra-abdominal organs

0 (0.00)

Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue

0 (0.00)

-0.53 [-2.22, 1.15]

Carcinoma in situ of breast, lobular

Glycogen storage disease

0 (0.00)

Severe visual impairment, binocular

0 (0.00)

0.00 [-0.78, 0.79]

Carcinoma in situ of vulva

-0.36 [-1.37, 0.66]

Leiomyoma of uterus

22 (0.05)

Other disorders of carbohydrate metabolism

0 (0.00)

-0.29 [-1.17, 0.59]

Coccidioidomycosis

Hypertrophy of tongue papillae

0 (0.00)

0.30 [-0.99, 1.59]

Acné excoriée

0 (0.00)

Carcinoma in situ, eye

Poisoning by medicine, drug-induced

0 (0.00)

Contact with and exposure to communicable diseases

14 (0.08)

Malignant neoplasm of endocrine gland

Malignant neoplasm of testis, excluding all cancers (controls excluding all cancers)

0.33 [-0.85, 1.52]

Pulmonary haemorrhage originating in the perinatal period

Persons with potential health hazards related to communicable diseases

21 (0.10)

Other and unspecified intracranial injuries

Erythema intertrigo

-0.51 [-1.82, 0.80]

Asthma (mode)

53 (0.09)

Malignant neoplasm of breast, HER2-negative, excluding all cancers (controls excluding all cancers)

25 (0.10)

Convulsions of newborn

Whooping cough

0 (0.00)

0.28 [-1.64, 2.21]

Other abnormal findings of blood chemistry

Contact urticaria

0 (0.00)

-0.19 [-1.00, 0.62]

L02BA Anti-estrogens

8 (0.11)

Sequelae of injuries of upper limb

Presence of other devices

11 (0.10)

Conduct disorder

Phlebitis and thrombophlebitis of other deep vessels of lower extremities, drug-induced

-0.13 [-0.82, 0.55]

Plasmodium vivax malaria

Malignant neoplasm of gallbladder, excluding all cancers (controls excluding all cancers)

0 (0.00)

Neurofibromatosis, type 2

0 (0.00)

0.28 [-0.38, 0.93]

Exposure to ignition or melting of other clothing and apparel

0 (0.00)

Toxic liver disease with chronic active hepatitis, drug-induced

Other neonatal haemorrhages

Primary thrombophilia

Amyloidosis

Testicular hyperfunction

Tetraplegia

-0.16 [-0.95, 0.63]

Dental caries 1 and operation codes

152 (0.07)

Other conditions originating in the perinatal period

Primary ovarian failure

0 (0.00)

0.54 [-1.12, 2.20]

Carcinoma in situ of anus and anal canal

Methaemoglobinaemia

Toxic encephalopathy

0 (0.00)

-0.54 [-1.46, 0.39]

Thyrotoxicosis, other and/or unspecified

8 (0.09)

Benign lipomatous neoplasm of skin and subcutaneous tissue of other and unspecified sites

0 (0.00)

0.52 [-1.30, 2.35]

Transitory endocrine and metabolic disorders specific to fetus and newborn

0 (0.00)

Malignant neoplasm of breast, excluding all cancers (controls excluding all cancers)

25 (0.10)

-0.20 [-0.64, 0.25]

Cytomegaloviral hepatitis

-0.22 [-0.97, 0.53]

Malignant neoplasm of oropharyng

0 (0.00)

Other acute viral hepatitis

Cluster headache, wide,, including avohilmo

0 (0.00)

Acute lymphocytic leukaemia, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.24 [-1.09, 0.60]

Diffuse large B-cell lymphoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.10 [-0.89, 0.69]

Craniosynostosis EXCLUDE syndromes

0 (0.00)

0.59 [-0.40, 1.58]

Duodenal ulcer - Acute without haemorrhage or perforation, drug-induced

Intentional self-harm by unspecified means

Mood disorders, excluding more controls

44 (0.06)

Cellulitis of external ear

0.31 [-1.08, 1.71]

Other conditions of integument specific to fetus and newborn

0 (0.00)

Open wound of head

20 (0.07)

Other/unspecified reactive arthropathies

6 (0.20)

External causes of morbidity and mortality

204 (0.08)

Unspecified renal colic

0 (0.00)

0.55 [-0.59, 1.69]

Familial dysautonomia

Molybdenum deficiency, drug-induced

Malignant neoplasm, without specification of site, excluding all cancers (controls excluding all cancers)

Liposarcoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.54 [-1.65, 0.56]

Delayed puberty

0 (0.00)

0.21 [-0.77, 1.19]

Contact with other specified venomous animals

0 (0.00)

Injury of muscle and tendon at forearm level

Early lumbar disc prolapse operation

Other birth injuries

0 (0.00)

Nail disorders in diseases classified elsewhere

Benign neoplasm: Mesothelial tissue of peritoneum

Malignant neoplasm of pyriform sinus, excluding all cancers (controls excluding all cancers)

0 (0.00)

Manganese deficiency

Alopecia mucinosa, drug-induced

Polytrichia

Somnolence, stupor and coma

Chloasma

0 (0.00)

-0.28 [-1.02, 0.46]

Actinic granuloma

Psoriatic and enteropathic arthropathies

Failure and rejection of transplanted organs and tissues

Adenocarcinoma and ductal carcinoma of pancreas, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.95 [-2.34, 4.24]

Cleft hard palate NOS

0.03 [-0.58, 0.64]

Secondary malignant neoplasm of respiratory and digestive organs, excluding all cancers (controls excluding all cancers)

Alcoholic myopathy

Maple-syrup-urine disease

0 (0.00)

Correction of physiology of bite - demanding therapy visit

0 (0.00)

Congenital syphilis

Colitis, primary sclerosing

Contracture of muscle

0 (0.00)

-0.19 [-0.97, 0.59]

Common variable immunodeficiency with predominant abnormalities of T-cell numbers and function

0 (0.00)

Other/unspecified seropositive rheumatoid arthritis (ICD-10)

8 (0.07)

Drug-induced gout

0 (0.00)

-0.25 [-1.00, 0.50]

Other specified metabolic disorders, drug-induced

Chronic postrheumatic arthropathy [Jaccoud]

0 (0.00)

Psychiatric diseases

103 (0.07)

Obesity and other hyperalimentation

33 (0.10)

Malignant neoplasm of peripheral nerves and autonomic nervous system

Barrett oesophagus

-0.11 [-0.90, 0.69]

Birth injury to skeleton

0 (0.00)

Carcinoma in situ of skin of upper limb, including shoulder

0 (0.00)

Acquired hypertrichosis lanuginosa

Malignant neoplasm of other and unspecified parts of mouth, excluding all cancers (controls excluding all cancers)

0 (0.00)

Arenaviral haemorrhagic fever

Use of other anti-dementia drugs, combinations

Appendicitis, broad definition

35 (0.08)

Carcinoma in situ of cervix uteri, endocervix

0 (0.00)

Use of selegiline

0 (0.00)

Benign neoplasm: Vagina

0 (0.00)

Other and unspecified disorders of globe

0 (0.00)

-0.87 [-2.23, 0.48]

Assault by hanging, strangulation and suffocation

0 (0.00)

Encephalopathy

0 (0.00)

0.40 [-0.54, 1.35]

Oral corticosteroids

72 (0.10)

Chlamydia psittaci infection

0 (0.00)

Viral agents as the cause of diseases classified to other chapters

0 (0.00)

Disorders of adult personality and behaviour

6 (0.04)

Metabolic disorder, unspecified, drug-induced

Unspecified effects of radiation

0 (0.00)

Other intracranial haemorrhages

0 (0.00)

-0.89 [-2.44, 0.66]

Chromophobe cell carcinoma of kidney

0 (0.00)

Disorders of gallbladder, biliary tract and pancreas

58 (0.09)

Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx

Pedestrian injured in collision with pedal cycle

0 (0.00)

Intrahepatic Cholestasis of Pregnancy (ICP) , excluding more controls

0.42 [-0.40, 1.23]

Other degenerative diseases of the basal ganglia

Telogen effluvium

0 (0.00)

0.03 [-0.66, 0.73]

Other conditions related to polyarteritis nodosa

0 (0.00)

0.64 [-0.48, 1.75]

Drugs, medicaments and biological substances causing adverse effects in therapeutic use

Dental caries 3

160 (0.07)

Asthma-related pneumonia or sepsis

20 (0.11)

Unilateral visual impairment (ICD-8)

Myoclonus, drug-induced

0 (0.00)

Congenital absence, atresia and stenosis of large intestine

0 (0.00)

-0.01 [-0.52, 0.50]

Malignant neoplasm of placenta

Disorders of purine and pyrimidine metabolism, other/unspecified

Premenstrual syndrome

0 (0.00)

-0.89 [-2.51, 0.73]

Agent resistant to penicillin and related antibiotics

0 (0.00)

Other mycoses, not elsewhere classified/unspecified

0 (0.00)

0.71 [-0.64, 2.06]

Myositis

0 (0.00)

0.23 [-1.03, 1.49]

Leiomyosarcoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.87 [-2.64, 0.90]

Radiodermatitis

0 (0.00)

-0.58 [-1.52, 0.37]

Benign neoplasm: Lip

0 (0.00)

Helminthiases

0 (0.00)

-0.08 [-1.37, 1.22]

Other rupture of muscle

0 (0.00)

-0.61 [-1.94, 0.72]

Other drug-induced osteomalacia in adults

Chronic drug-induced interstitial lung disorders

-0.39 [-1.15, 0.37]

Transitional cell carcinoma of kidney

Malignant neoplasm of stomach

Other and unspecified disorders of orbit

0 (0.00)

0.57 [-0.62, 1.76]

Benign lipomatous neoplasm of skin and subcutaneous tissue of trunk

6 (0.10)

Bitten or stung by nonvenomous insect and other nonvenomous arthropods

Manic episode

0 (0.00)

-0.02 [-0.73, 0.69]

Inguinal hernia, unilateral

0 (0.00)

-0.44 [-1.45, 0.56]

Pneumocystosis

0.05 [-1.22, 1.32]

Carcinoma in situ of anus and anal canal

Systemic sclerosis,strict definition

-0.05 [-0.92, 0.81]

Asthma, including avohilmo

83 (0.10)

Triptan medication for migraine, min. 3 purchases

17 (0.05)

Melanocytic naevi of eyelid, including canthus

0 (0.00)

Malignant neoplasm of accessory sinuses, excluding all cancers (controls excluding all cancers)

0 (0.00)

Persons with potential health hazards related to family and personal history and certain conditions influencing health status

88 (0.11)

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

46 (0.08)

Accidental poisoning by and exposure to pesticides

0 (0.00)

Myotonic disorders

0 (0.00)

Colour vision deficiencies

0 (0.00)

0.35 [-0.53, 1.24]

Pneumonia, organism unspecified

55 (0.08)

Nezelof syndrome

0 (0.00)

0.01 [-0.81, 0.83]

Bullous keratopathy

1.00 [-0.77, 2.77]

Other and unspecified bullous disorders

0.09 [-1.12, 1.31]

Seminoma of testis

Benign neoplasm of soft tissue of retroperitoneum and peritoneum

0 (0.00)

0.55 [-0.75, 1.86]

Defect, injury or illness of neck

0 (0.00)

Disturbances of skin sensation

10 (0.08)

Use of ocrelizumab

Melanocytic naevi of ear and external auricular canal

0 (0.00)

0.58 [-1.37, 2.54]

Polyp of middle ear

0.08 [-0.47, 0.62]

Other chronic figurate erythema

Use of edaravone

Benign neoplasm: Ill-defined sites within the digestive system

0 (0.00)

0.40 [-1.27, 2.07]

Convulsions, not elsewhere classified

Benign neoplasm: Mesothelial tissue of other sites/unspecified

0 (0.00)

Monocytic leukaemia

0.10 [-0.61, 0.81]

Other early complications of trauma

16 (0.09)

Carcinoma in situ, thyroid and other endocrine glands

Alzheimer’s disease (Early onset), excluding more controls

-0.52 [-2.43, 1.40]

Chronic myeloproliferative disease

0 (0.00)

-0.75 [-2.13, 0.64]

Renal agenesis and other reduction defects of kidney

-0.57 [-1.87, 0.73]

Melanocytic naevi of scalp and neck

Other abnormal findings in urine

0 (0.00)

Thyrotoxicosis with toxic single thyroid nodule

0 (0.00)

0.10 [-0.81, 1.00]

Carcinoma in situ of other and unspecified digestive organs

Disorders of puberty

0 (0.00)

HSIL lesion of the vagina

0.56 [-0.65, 1.76]

Polyneuropathy due to other toxic agents

0 (0.00)

Postinfectious hypothyroidism

0 (0.00)

-0.21 [-1.01, 0.58]

Acne vulgaris

Tic and related disorders

0 (0.00)

0.84 [-0.60, 2.28]

Injury of nerves at hip and thigh level

0 (0.00)

Benign neoplasm: Ill-defined sites within the digestive system

0 (0.00)

IPHG Phlebitis and thrombophlebitis of intracranial venous sinuses

0 (0.00)

Air embolism (traumatic)

Carcinoma in situ of rectum

0.43 [-0.83, 1.69]

Sequelae of external causes of morbidity and mortality

6 (0.05)

Benign neoplasm: Retina

0 (0.00)

-0.13 [-0.95, 0.70]

Carcinoma in situ, other and unspecified urinary organs

Injury of unspecified body region

Anuria and oliguria

0 (0.00)

Total colectomy operation

Malignant neoplasm of breast, HER2-negative

24 (0.10)

Benign neoplasm: Female genital organ, unspecified

0 (0.00)

-0.55 [-1.65, 0.55]

Handgun discharge

Crohn disease

Bilateral

0 (0.00)

Disorders of thyroid, IBD co-morbidities

14 (0.10)

Burkitt lymphoma

0 (0.00)

Other adrenocortical overactivity

0 (0.00)

-0.20 [-1.03, 0.62]

Lichen ruber moniliformis

Exposure to excessive natural heat

Drug-induced systemic lupus erythematosus

0 (0.00)

-1.00 [-2.63, 0.63]

Endovascular or surgical operations to intracerebral aneurysms

Lupus erythematosus

0 (0.00)

0.22 [-0.56, 1.00]

Tetanus

Disorders of muscle tone of newborn

0 (0.00)

0.22 [-0.48, 0.91]

Social disorders starting during childhood or adolescence

0 (0.00)

Sequelae of poliomyelitis

0 (0.00)

0.33 [-0.71, 1.38]

Endometriosis in cutaneous scar

0 (0.00)

0.19 [-0.57, 0.96]

Disorders of plasma-protein metabolism, not elsewhere classified, drug-induced

Cardiovascular disorders originating in the perinatal period

-0.16 [-0.94, 0.61]

Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinaemia

0 (0.00)

Type 2 diabetes, definitions combined, including avohilmo

66 (0.07)

Exposure to excessive cold of man-made origin

Surgical and other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

29 (0.09)

Hypertrophy of bone

0 (0.00)

-0.56 [-1.50, 0.38]

Embolism and thrombosis of abdominal aorta

0.18 [-0.55, 0.91]

Other benign neoplasm of uterus: Cervix uteri

0 (0.00)

-0.16 [-0.96, 0.64]

Toxic liver disease with hepatitis, not elsewhere classified, drug-induced

Other sudden death, cause unknown

Acute myringitis

0 (0.00)

-0.55 [-1.81, 0.72]

Parodontitis, under 40 years

0 (0.00)

Use of metixene

0 (0.00)

Congenital ectropion

Infection due to other mycobacteria

0 (0.00)

-0.86 [-2.43, 0.71]

Venous complications and haemorrhoids in pregnancy

0 (0.00)

Benign neoplasm: Mesothelial tissue of peritoneum

Acquired ichthyosis

0 (0.00)

Coxibs

85 (0.07)

Ascariasis

Chromophobe cell carcinoma of kidney, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.37 [-1.18, 0.44]

Dipeptidyl peptidase 4 (DPP-4) inhibitors

7 (0.14)

Hypothyroidism (congenital or acquired)

59 (0.09)

Other transitory neonatal electrolyte and metabolic disturbances

Elevated erythrocyte sedimentation rate and abnormality of plasma viscosity

SLE, strict definition

Other or unspecified common variable immunodeficiency

-0.13 [-0.84, 0.58]

Malignant neoplasm of ureter

0 (0.00)

Dengue

Malignant neoplasm of oral cavity

Congenital malformation syndromes predominantly affecting facial appearance

Open wound of hip and thigh

Other injuries of upper limb, level unspecified

Deficiency of vitamin E

Benign neoplasm: Female genital organ, unspecified

0 (0.00)

Other and unspecified injuries of abdomen, lower back and pelvis

Adverse effects, not elsewhere classified

Mature T/NK-cell lymphomas, hilmo, excluding all cancers

0 (0.00)

-0.61 [-1.82, 0.61]

Open wound of thorax

Benign neoplasm: Prostate

0 (0.00)

0.00 [-0.86, 0.87]

Respiratory tuberculosis, clinically confirmed

0 (0.00)

Stevens-Johnson syndrome, drug-induced

Human immunodeficiency virus [HIV] disease resulting in other specified diseases

Other primary thrombocytopenia

0 (0.00)

0.59 [-0.48, 1.67]

Diseases of pulp and periapical tissues, including avohilmo

101 (0.07)

Infection of intervertebral disc (pyogenic)

1.00 [-0.66, 2.66]

Vasculitis limited to skin, not elsewhere classified

0 (0.00)

Degeneration of nervous system due to alcohol

0 (0.00)

Rheumatic fever with heart involvement

0.01 [-0.73, 0.75]

Injuries to the elbow and forearm

27 (0.07)

Autoimmune thyroiditis

0 (0.00)

1.00 [-0.72, 2.72]

Use of memantine

10 (0.09)

Benign neoplasm of other and unspecified female genital organs

0 (0.00)

Senility

0 (0.00)

Other perinatal digestive system disorders

Maternal care for (suspected) damage to fetus from alcohol

0 (0.00)

0.62 [-0.42, 1.67]

Bacterial meningoencephalitis and meningomyelitis

Oesophageal varices

0 (0.00)

0.41 [-0.66, 1.47]

Refsum disease

Cleft lip and cleft lip and palate

-1.00 [-2.67, 0.67]

Ovarian dysfunction: estrogen excess

Sequelae of hyperalimentation

0 (0.00)

-0.30 [-0.98, 0.38]

Inhalation and ingestion of other objects causing obstruction of respiratory tract

0 (0.00)

Carcinoma in situ of other/unspecified female genital organs

Lupus erythematosus, drug-induced

0 (0.00)

Adhesive middle ear disease

0 (0.00)

-0.40 [-1.62, 0.82]

Disorders of other digestive organs in diseases classified elsewhere

Hereditary nephropathy, not elsewhere classified

0 (0.00)

-0.40 [-1.30, 0.49]

Murder, homicide, or other assault by handgun discharge

Injury of blood vessels of thorax

0 (0.00)

Ischaemic Stroke, excluding all haemorrhages

26 (0.08)

Diseases of the ear and mastoid process

98 (0.08)

Chronic myeloid leukaemia [CML], BCR/ABL-positive

-0.20 [-1.34, 0.94]

Smallpox

Laparoscopic right hemicolectomy

0 (0.00)

Reduction defects of upper limb

-0.57 [-1.55, 0.40]

Carcinoma in situ of other/unspecified male genital organs

Tuberculosis of other organs

Malignant neoplasm of trachea, excluding all cancers (controls excluding all cancers)

Other sideroblastic anaemias

0.30 [-0.51, 1.11]

Personal history of allergy to analgesic agent

0 (0.00)

Secondary parkinsonism, excluding more controls

0 (0.00)

-0.44 [-1.60, 0.71]

Unspecified nephritic syndrome, drug-induced

Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.08 [-0.94, 1.11]

Vitamin A deficiency

0 (0.00)

-0.09 [-0.90, 0.72]

Aortic valve malfunction, age under 60 years

6 (0.15)

Carcinoma in situ of vagina

0 (0.00)

Carcinoma in situ of bronchus and lung

Fistulae involving female genital tract

0.18 [-1.55, 1.91]

Anencephaly and similar malformations

Secondary and unspecified malignant neoplasm of lymph nodes, excluding all cancers (controls excluding all cancers)

Phantom limb syndrome with pain

0 (0.00)

-0.38 [-1.19, 0.42]

Malignant neoplasm of other and ill-defined digestive organs

0 (0.00)

Medicines for HER+ breast cancer

14 (0.09)

Right ventricular outflow tract obstruction

0 (0.00)

-0.29 [-2.67, 2.09]

Disorders of accommodation

Toxic effect of other noxious substances eaten as food

Secondary thrombocytopenia, drug-induced

0 (0.00)

Injury of urinary and pelvic organs

Disorder of amino-acid metabolism, other/unspecified

Acne tropica

Female pelvic inflammatory disorders in diseases classified elsewhere

0 (0.00)

0.23 [-0.55, 1.01]

Carcinoma in situ of bronchus and lung

Other disorders of amino-acid metabolism

0 (0.00)

0.43 [-0.55, 1.41]

Type of accident

Liposarcoma

0 (0.00)

Brain glioblastoma and astrocytoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.04 [-1.11, 1.19]

Arthropod-borne viral fevers and viral haemorrhagic fevers

Bitten or struck by other mammals

Carcinoma in situ of skin of eyelid, including canthus

0 (0.00)

Benign neoplasm: Skin of upper limb, including shoulder

0 (0.00)

Benign neoplasm: Trachea

Molybdenum deficiency

Undefined dementia

Parasetamol

176 (0.08)

Disorders of branched-chain amino-acid metabolism and fatty-acid metabolism

Internuclear ophthalmoplegia

0 (0.00)

0.37 [-0.34, 1.09]

Benign neoplasm: Mesothelial tissue of pleura

Haematosalpinx/Haematoma of broad ligament

0 (0.00)

0.05 [-0.52, 0.61]

Hypervitaminosis D

Beau lines

0 (0.00)

Malignant neoplasm of oesophagus, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.62 [-2.00, 0.76]

Non-selective monoamine reuptake inhibitors

16 (0.08)

Fissure and fistula of anal and rectal regions

14 (0.11)

Strongyloidiasis

0 (0.00)

Open wound of abdomen, lower back and pelvis

Presence of other functional implants

46 (0.14)

Pedestrian injured in collision with two- or three-wheeled motor vehicle

0 (0.00)

Galactorrhea

0 (0.00)

Benign neoplasm: Ascending colon

Carcinoma in situ of oral cavity

0.28 [-0.43, 0.98]

Macular hole, drug-induced

0 (0.00)

Afelimomab

Myocardial infarction

23 (0.06)

Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue

0 (0.00)

Reactions and intoxications due to drugs administered to fetus and newborn

Tramadol

51 (0.10)

Malignant neoplasm of hypopharynx

0 (0.00)

Congenital malformations of breast

0 (0.00)

-0.15 [-1.30, 0.99]

Abnormal weight loss

Benign neoplasm: Skin of other and unspecified parts of face

Dental invagination

Benign neoplasm: Ciliary body

Juvenile dermatomyositis

0 (0.00)

Respiratory tuberculosis, bacteriologically and histologically confirmed

0 (0.00)

Benign neoplasm: Conjunctiva

25 (1.70)

Other bursitis, not elsewhere classified

0 (0.00)

-0.70 [-2.10, 0.70]

Transient synovitis

0 (0.00)

-0.41 [-1.37, 0.55]

Genetic anomalies of leukocytes

Malignant melanoma of skin, excluding all cancers (controls excluding all cancers)

-0.26 [-0.89, 0.37]

Injury of blood vessels at shoulder and upper arm level

0 (0.00)

Malignant neoplasm of bone and articular cartilage of other and unspecified sites

Use of piribedil

Dental operations, only avohilmo

187 (0.07)

Injury of nerves at lower leg level

Human immunodeficiency virus [HIV] disease resulting in malignant neoplasms

Pedestrian injured in collision with heavy transport vehicle or bus

0 (0.00)

Exposure to sunlight

0 (0.00)

Drug-induced nonautoimmune haemolytic anaemia

Symptoms and signs involving the skin and subcutaneous tissue

30 (0.08)

Gonococcal infection

0.02 [-0.79, 0.83]

Henoch-Schönlein purpura nephritis (HSPN)

0 (0.00)

0.29 [-0.50, 1.09]

Disorders of plasma-protein metabolism, not elsewhere classified

-0.49 [-1.83, 0.85]

Injury of nerves and lumbar spinal cord at abdomen, lower back and pelvis level

0 (0.00)

Changes in corneal membranes

0 (0.00)

-0.25 [-0.96, 0.46]

Parodontitis and operation codes

30 (0.06)

Choroidal degeneration

Hyperosmolality and hypernatraemia

0 (0.00)

1.00 [-1.58, 3.58]

Ovarian dysfunction, other/unspecified

0 (0.00)

0.50 [-0.64, 1.64]

Congenital malformations of gallbladder, bile ducts and liver

0 (0.00)

0.92 [-1.07, 2.90]

Lung transplant status

0 (0.00)

0.20 [-0.78, 1.18]

Unspecified urinary incontinence

Benign neoplasm: Connective and other soft tissue of pelvis

0 (0.00)

Actinomycosis

0 (0.00)

0.11 [-0.93, 1.15]

Other symptoms and signs involving the nervous and musculoskeletal systems

17 (0.08)

Human immunodeficiency virus [HIV] disease

Miliaria rubra

Chronic suppurative otitis media, including avohilmo

Colorectal adenocarcinoma, excluding all cancers (controls excluding all cancers)

0.28 [-0.42, 0.98]

Hypoplasia of dental enamel, including avohilmo

-1.00 [-2.96, 0.96]

Morphin

0 (0.00)

Periodontosis

0 (0.00)

Congenital pneumonia

5-aminosalicylic acid

8 (0.07)

Arthropathic psoriasis

Neurofibromatosis, type 1

0 (0.00)

0.17 [-0.81, 1.14]

Fracture of upper limb, level unspecified

Hypospadias

0 (0.00)

-0.07 [-0.79, 0.65]

Contaminated medical or biological substances

Thyroid crisis or storm

0 (0.00)

0.18 [-0.62, 0.98]

Endocrine, nutritional and metabolic diseases

173 (0.08)

Other congenital malformations of intestine

0 (0.00)

0.55 [-0.62, 1.72]

Benign neoplasm: Spinal meninges

0 (0.00)

Pupillary membranes and other adhesions and disruptions of iris and ciliary body

0 (0.00)

-0.45 [-1.24, 0.33]

Intrahepatic Cholestasis of Pregnancy (ICP) , incl. ICD-8, excluding more controls

0.32 [-0.37, 1.02]

Malignant neoplasm of retroperitoneum and peritoneum

0 (0.00)

Other proliferative retinopathy

0 (0.00)

-0.22 [-1.21, 0.77]

Taurodontism

Thiazolidinediones

Digestive system disorders of fetus and newborn

Implicit Sepsis

39 (0.09)

Haemangioma and lymphangioma, any site

5 (0.13)

Postpartum care and examination

7 (0.05)

Other psoriatic arthropathies

Foreign body in ear

Drowning to ice

Benign neoplasm: Other specified/unspecified intrathoracic organs (+ respiratory system NOS of Icd-9)

0 (0.00)

Macular pucker, drug-induced

Macular cyst, drug-induced

Nonvenereal syphilis

Noninfective disorders of pinna

0 (0.00)

-0.06 [-0.68, 0.55]

Metabolic disorder, other/unspecified

0 (0.00)

Xanthelasma of eyelid

0 (0.00)

-0.48 [-1.66, 0.71]

Pityriasis lichenoides chronica

0 (0.00)

-0.08 [-0.81, 0.65]

Achalasia of cardia

0 (0.00)

-1.00 [-2.98, 0.98]

Carcinoma in situ of oesophagus

Traumatic amputation of ankle and foot

0 (0.00)

Benign neoplasm: Prostate

0 (0.00)

Benign neoplasm: Hypopharynx

0 (0.00)

Cardiovascular diseases

210 (0.07)

Adenocarcinomas of cervix, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.05 [-1.03, 0.94]

Benign neoplasm: Descending colon

Acne varioliformis

0 (0.00)

-0.16 [-1.08, 0.75]

Fall on and from ladder

Benign neoplasm: Brain, unspecified

0 (0.00)

Benign lipomatous neoplasm of skin and subcutaneous tissue of head, face and neck

0 (0.00)

Benign neoplasm: Rectum/anal canal icd-9

0 (0.00)

Malignant neoplasm of rectum, excluding all cancers (controls excluding all cancers)

0.03 [-0.55, 0.61]

Malignant neoplasm of lip

0 (0.00)

Parkinson's disease, excluding more controls

Benign neoplasm: Liver

0 (0.00)

Mantle cell lymphoma

Vertiginous syndromes in diseases classified elsewhere

Mental retardation, excluding more controls

-0.68 [-2.07, 0.71]

Examination and observation for other reasons

34 (0.08)

Vibratory urticaria

Atlantoaxial subluxation

0 (0.00)

Injuries to the thorax

17 (0.08)

ICD-8 DM (Sub-endpoint used for defining DM endpoints)

Mixed disorder of acid-base balance

Hypercarotenaemia

Benign neoplasm: Pituitary gland, craniopharyngeal duct

7 (0.31)

Complications of procedures, not elsewhere classified

35 (0.08)

Malignant neoplasm of renal pelvis, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.44 [-3.71, 2.82]

Malignant neoplasm of eye, brain and central nervous system

12 (0.62)

Family history of certain disabilities and chronic diseases leading to disablement

Classical phenylketonuria

Leisure time condition

Other thrombophilia

Injury of nerves at ankle and foot level

0 (0.00)

Hepatomegaly and splenomegaly, not elsewhere classified

Unspecified drowning and submersion

0 (0.00)

Granulosa cell carcinoma of ovary

0 (0.00)

Oedema, not elsewhere classified

17 (0.11)

Post-traumatic wound infection, not elsewhere classified

0 (0.00)

Ovarian hyperstimulation (induction)

0.80 [-0.50, 2.10]

Mandibular prognathia AND surgery (LeFortI or BSSRO)

0 (0.00)

0.49 [-0.61, 1.59]

17 (0.05)

Malignant neoplasm of vagina

Osteogenesis imperfecta

Rash and other nonspecific skin eruption

5 (0.11)

Respiratory conditions due to inhalation of chemicals, gases, fumes and vapours

0 (0.00)

-0.74 [-2.18, 0.70]

Protein-energy malnutrition of moderate and mild degree

-0.42 [-1.45, 0.62]

Adrenomedullary hyperfunction

0 (0.00)

0.41 [-0.51, 1.32]

Hirsutism, drug-induced

0 (0.00)

0.14 [-0.47, 0.75]

Secondary uncertain malignant neoplasm, excluding all cancers (controls excluding all cancers)

12 (0.06)

Psoriasis (vulgaris), strict definition

0.28 [-0.47, 1.02]

Frostbite with tissue necrosis

0 (0.00)

Pyoderma gangrenosum

0 (0.00)

Sulfasalazine

15 (0.10)

Benign neoplasm: Heart

0 (0.00)

0.79 [-0.48, 2.06]

Rabies

Gout, FINNGEN

14 (0.11)

Liver disorders in diseases classified elsewhere

0 (0.00)

-0.04 [-0.74, 0.67]

Exposure to other specified factors

30 (0.07)

Pneumonia due to Haemophilus influenzae

0 (0.00)

-0.11 [-0.97, 0.75]

Diffuse brain injury

Biomechanical lesions, not elsewhere classified

0.90 [-0.73, 2.54]

Hereditary nephropathy, not elsewhere classified, drug-induced

Injuries to the shoulder and upper arm

32 (0.07)

Other misadventures during surgical and medical care

Chondromalacia

0 (0.00)

0.13 [-1.73, 1.99]

Other antidepressants

66 (0.07)

Bacterial agents resistant to antibiotics

0 (0.00)

Benign neoplasm of mouth and pharynx

Malignant neoplasm of tongue, excluding all cancers (controls excluding all cancers)

Fetal blood loss

Chondrosarcoma, excluding all cancers (controls excluding all cancers)

-0.88 [-2.29, 0.53]

Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances

5 (0.06)

Other and unspecified types of non-Hodgkin lymphoma, hilmo, excluding all cancers

-0.19 [-1.16, 0.77]

Glanders and melioidosis

0 (0.00)

Degeneration of the brain due to alcohol

0.29 [-1.12, 1.70]

Fracture of neck

0.19 [-1.26, 1.64]

Apocrine sweat disorders, other sweat gland disorders

0 (0.00)

0.29 [-0.60, 1.17]

Malignant neoplasm of tongue

Benign neoplasm: Peripheral nerves and autonomic nervous system

0 (0.00)

Polyglandular hyperfunction

Vitreous prolapse

0 (0.00)

0.24 [-0.53, 1.00]

Type 1 diabetes, strict definition, subgroup 1

Diffuse (eosinophilic) fasciitis

0 (0.00)

-0.24 [-0.86, 0.38]

Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs, excluding all cancers (controls excluding all cancers)

Striking against or struck by other objects

16 (0.10)

0 (0.00)

Melanoma in situ of lip

Noninfectious colitis NAS

5 (0.08)

Pulmonary eosinophilia, not elsewhere classified

0.17 [-0.81, 1.15]

Occupational exposure to risk-factors

0 (0.00)

Diabetes medication

Other lack of coordination

0 (0.00)

Abnormalities of ear ossicles

0 (0.00)

-0.65 [-1.78, 0.48]

Septicaemia

24 (0.12)

Use of mazaticol

Butylpyrazolidines

Exclusion endpoint for supernumerary teeth

0 (0.00)

Benign neoplasm: Other parts of oropharynx

0 (0.00)

Huntington disease

Blindness or visual impairment, binocular

0 (0.00)

-0.46 [-1.36, 0.45]

Maxillary hypoplasia

0 (0.00)

-0.00 [-0.72, 0.72]

Dental caries, including avohilmo

170 (0.07)

Superficial injury of hip and thigh

6 (0.09)

Schistosomiasis [bilharziasis]

Diphyllobothriasis and sparganosis

0 (0.00)

Fourth [trochlear] nerve palsy

Colorectal neuroendocrine tumor and carcinoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.38 [-1.33, 0.58]

Other viral hepatitis

Gastrojejunal ulcer

0 (0.00)

-0.24 [-1.59, 1.11]

Trichomoniasis

-0.72 [-1.99, 0.55]

Tympanosclerosis

0 (0.00)

0.67 [-0.48, 1.82]

Traumatic subdural haemorrhage

5 (0.08)

Tuberculosis of nervous system

Any dementia, excluding more controls

10 (0.05)

-0.20 [-0.85, 0.45]

Drug-induced obesity

0 (0.00)

0.30 [-0.77, 1.37]

Benign neoplasm: Larynx

Disorders of puberty, all

0 (0.00)

Sweet's syndrome

0 (0.00)

Malignant neoplasm of bone and articular cartilage of limbs, excluding all cancers (controls excluding all cancers)

Immobility syndrome (paraplegic)

Keratosis follicularis et parafollicularis in cutem penetrans [Kyrle]

0 (0.00)

Congenital malformations of lung

0 (0.00)

-0.34 [-1.13, 0.44]

Other disturbances of temperature regulation of newborn

Explosion of other materials

0 (0.00)

Isolated proteinuria

0 (0.00)

Diphtheria

0 (0.00)

0.27 [-0.39, 0.93]

Congenital myopathies

-0.11 [-0.73, 0.51]

Mandibular prognathia

0 (0.00)

Agent resistant to other and unspecified antibiotics

Use of tacrine

Hereditary choroidal dystrophy

Edwards' syndrome and Patau's syndrome

Visual disturbances in diseases classified elsewhere

0 (0.00)

COPD/asthma related infections

133 (0.08)

ILD medications

101 (0.10)

Benign neoplasm: Lower jaw bone

0 (0.00)

Petrositis

Benign neoplasm: Vertebral column

0 (0.00)

Other osteochondrodysplasias

0.06 [-1.24, 1.36]

Non-small cell lung cancer, adenocarcinoma, helper endpoint

Superficial injury of ankle and foot

5 (0.09)

Traumatic subarachnoid haemorrhage

0 (0.00)

Hereditary angioödema type 2

Disorders of urea cycle metabolism

General hospital and personal-use devices associated with adverse incidents

0 (0.00)

Magnesium deficiency, drug-induced

Benign neoplasm: Lower jaw bone

0 (0.00)

0.10 [-0.74, 0.93]

Melanocytic naevi, other sites/unspecified

Golimumab

Malignant neoplasm of small intestine, excluding all cancers (controls excluding all cancers)

-0.40 [-1.58, 0.78]

Fall on and from stairs and steps

8 (0.07)

Neuroendocrine tumor and carcinoma of pancreas

0 (0.00)

Merkel cell carcinoma of skin, excluding all cancers (controls excluding all cancers)

Psoriatic arthropathies, strict definition

Reduction defects of unspecified limb

Abnormality of white blood cells, not elsewhere classified

0 (0.00)

Spirochaetal infections, other/unspecified

Injuries to the neck

9 (0.08)

Anxiety disorders, excluding more controls

39 (0.07)

0.30 [-0.18, 0.78]

Deaf mutism, not elsewhere classified

0 (0.00)

0.44 [-0.83, 1.71]

L04AX Other immunosuppressants

21 (0.07)

Bruxism

0 (0.00)

Corneal pigmentations and deposits, drug-induced

Benign neoplasm: Pharynx, unspecified

0 (0.00)

0.39 [-0.56, 1.34]

Exclusions for E4_PCOS_BROAD

11 (0.14)

Congenital malformations of spine and bony thorax

-0.39 [-1.53, 0.74]

Other retinal disorders in diseases classified elsewhere

0 (0.00)

0.29 [-0.47, 1.06]

Malignant neoplasm of vagina, excluding all cancers (controls excluding all cancers)

-0.10 [-0.83, 0.63]

Benign neoplasm: Connective and other soft tissue of upper limb, including shoulder

Secondary polycythaemia

0 (0.00)

0.42 [-0.53, 1.38]

Congenital absence, atresia and stenosis of small intestine

Exposure to electric transmission lines

0 (0.00)

Follow-up examination after treatment for malignant neoplasms

Victim of lightning

IBD (strict) with PSC

0 (0.00)

-0.47 [-1.38, 0.43]

Cardiac murmurs and other cardiac sounds

Otorrhagia

0 (0.00)

0.44 [-0.85, 1.73]

Foreign body in respiratory tract

Pain, not elsewhere classified

12 (0.09)

Acute epiglottitis

-0.13 [-1.22, 0.96]

Subacute thyroiditis

-0.22 [-1.24, 0.80]

Benign neoplasm: Connective and other soft tissue of pelvis

0 (0.00)

-0.36 [-1.19, 0.47]

Monoplegia

-0.47 [-1.54, 0.59]

Cystic fibrosis with pulmonary manifestations

0 (0.00)

Acne conglobata

0.21 [-0.55, 0.97]

Benign lipomatous neoplasm of skin and subcutaneous tissue of limbs

Fractures involving multiple body regions

-0.39 [-1.21, 0.43]

Erythema marginatum

Headache

46 (0.11)

Anti-inflammatory and antirheumatic products, non-steroids

282 (0.07)

Symptoms and signs involving cognition, perception, emotional state and behaviour

63 (0.10)

Organic, including symptomatic, mental disorders

24 (0.08)

Malignant neoplasm, excluding all cancers (controls excluding all cancers)

94 (0.07)

-0.13 [-0.55, 0.28]

Major coronary heart disease event excluding revascularizations

36 (0.07)

Carcinoma in situ of other/unspecified female genital organs

Toxic effect of corrosive substances

Motor- or nonmotor-vehicle accident, type of vehicle unspecified

Felty syndrome

0 (0.00)

1.00 [-0.67, 2.67]

Melanocytic naevi of other and unspecified parts of face

Upper arm

0 (0.00)

Benign neoplasm: Bronchus and lung

0 (0.00)

Lipid storage disorder, other/unspecified

Polyneuropathies and other disorders of the peripheral nervous system

7 (0.07)

Diabetes insipidus

0 (0.00)

0.79 [-1.10, 2.67]

Miliaria, unspecified

Other respiratory conditions originating in the perinatal period

Postimmunization arthropathy, drug-induced

Intestinal helminthiases, other/unspecified

Complications specific to multiple gestation

0 (0.00)

0.80 [-0.57, 2.18]

Disorders of fructose metabolism

Pelvic region

Budesonide

6 (0.09)

Gastrointestinal stromal tumor and sarcoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.11 [-1.24, 1.01]

Oesophagitis, drug-induced

0 (0.00)

-0.13 [-0.98, 0.73]

Malignant neoplasm of hypopharynx, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.42 [-0.69, 1.53]

Voice disturbances

Polyglandular dysfunction

0 (0.00)

0.21 [-0.41, 0.83]

KRA_PSY_EATING, excluding more controls

0 (0.00)

0.11 [-0.92, 1.13]

Codeine

66 (0.08)

Use of profenamine

Tarsal tunnel syndrome

0 (0.00)

-0.09 [-0.97, 0.78]

Toxic liver disease with fibrosis and cirrhosis of liver, drug-induced

0 (0.00)

Alcohol induced polyneuropathy

0 (0.00)

-0.18 [-1.07, 0.70]

Lichen planus, including avohilmo

6 (0.08)

Histoplasmosis

0 (0.00)

Sickle-cell disorders

0.40 [-0.36, 1.17]

Moderate visual impairment, monocular

0 (0.00)

-0.04 [-0.76, 0.69]

Malignant neoplasm of other and ill-defined sites

Postpartum hemorraghe, all women as controls

-0.40 [-1.33, 0.54]

Brain medulloblastoma, excluding all cancers (controls excluding all cancers)

Malignant neoplasm of meninges, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.22 [-0.69, 1.12]

Rhinophyma

-0.21 [-0.99, 0.56]

Hypothermia of newborn

0 (0.00)

Traction detachment of retina

0 (0.00)

0.27 [-0.94, 1.48]

Malignant neoplasm of oropharynx

0 (0.00)

Congenital malformations of the respiratory system

0 (0.00)

Foreign body in alimentary tract

Aspergillosis

0 (0.00)

0.15 [-0.82, 1.12]

Purine nucleoside phosphorylase [PNP] deficiency

Circumscribed brain atrophy

0.08 [-0.76, 0.92]

Injury of muscle and tendon at hip and thigh level

Malignant neoplasm of breast, ER-positive, excluding all cancers (controls excluding all cancers)

13 (0.09)

-0.19 [-0.68, 0.30]

Diseases of tongue

Alopecia areata

0 (0.00)

-0.93 [-2.49, 0.63]

Thalassaemia trait

Other benign neoplasm of uterus: Other parts/unspecified

Carcinoma in situ of lip, oral cavity and pharynx

0 (0.00)

COPD, hospital admissions

19 (0.08)

Other special examinations and investigations of persons without complaint or reported diagnosis

135 (0.09)

Open wound of wrist and hand

19 (0.08)

Burns and corrosions of multiple body regions

Mandibular hypoplasia

0 (0.00)

0.29 [-0.81, 1.39]

Chromomycosis and phaeomycotic abscess

0 (0.00)

Other abnormal immunological findings in serum

0 (0.00)

Other chorioretinal disorders in diseases classified elsewhere

Other specified disorders of eye and adnexa in diseases classified elsewhere

Findings of drugs and other substances, not normally found in blood

0 (0.00)

Pulmonary heart disease, diseases of pulmonary circulation

6 (0.04)

Drug-induced hypoglycaemia without coma

0.46 [-0.76, 1.68]

Carcinoma in situ of other/unspecified digestive organs

0 (0.00)

Disorders of pyruvate metabolism and gluconeogenesis

Ainhum

Effects of foreign body entering through natural orifice

12 (0.10)

Calcific aortic valvular stenosis, including rheumatic fever

8 (0.06)

Benign neoplasm: Kidney

Other and unspecified injuries of ankle and foot

Eosinophilic cellulitis [Wells]

Contact with blunt object, undetermined intent

Other haemoglobinopathies

0.08 [-0.52, 0.69]

Granuloma faciale [eosinophilic granuloma of skin]

Striae atrophicae

0 (0.00)

0.26 [-1.95, 2.48]

Myelodysplastic syndrome

Benign neoplasm of other and unspecified endocrine glands

12 (0.22)

malignant neoplasm of female genital organs

6 (0.10)

Disorders of sexual preference

0.12 [-0.51, 0.75]

Use of rivastigmine

Immunization not carried out

Phlebitis and thrombophlebitis of femoral vein, drug-induced

Degenerative conditions of globe

0 (0.00)

-0.16 [-1.01, 0.69]

Nephropathy induced by heavy metals, drug-induced

Fenamates

7 (0.05)

Other cystitis, drug-induced

Malignant neoplasm of other and ill-defined digestive organs, excluding all cancers (controls excluding all cancers)

0 (0.00)

Direct fill therapy

10 (0.17)

Acute generalized exanthematous pustulosis

Benign neoplasm: Brain, supratentorial

Hidradenitis suppurativa

0.09 [-0.52, 0.69]

Malignant neoplasm of rectosigmoid junction

Fetus and newborn affected by noxious influences transmitted via placenta or breast milk

0 (0.00)

Rhabdomyosarcoma, excluding all cancers (controls excluding all cancers)

0.02 [-0.58, 0.62]

Secondary and unspecified malignant neoplasm of lymph nodes

Non-Hodgkin lymphoma, all, excluding all cancers (controls excluding all cancers)

9 (0.16)

-0.23 [-0.92, 0.47]

Sequelae of injuries involving multiple and unspecified body regions

0 (0.00)

Immune checkpoint inhibitor medicines

Carcinoma in situ of other and unspecified sites

Paracoccidioidomycosis

Defects of catalase and peroxidase

0 (0.00)

Follicular adenocarcinoma of thyroid gland, excluding all cancers (controls excluding all cancers)

-0.23 [-1.15, 0.70]

Neonatal aspiration syndromes

Dyslexia and other symbolic dysfunctions, not elsewhere classified

0 (0.00)

Other and unspecified medical devices associated with adverse incidents

0 (0.00)

Lumbosacral plexus disorders

0 (0.00)

0.07 [-0.57, 0.71]

Melanocytic naevi of lip

0 (0.00)

-0.73 [-2.87, 1.42]

Unspecified severe protein-energy malnutrition

0.32 [-0.36, 1.00]

Schizotypal disorder

0.82 [-0.48, 2.12]

Acute posthaemorrhagic anaemia

0 (0.00)

0.34 [-1.81, 2.49]

Optic atrophy

0 (0.00)

-0.25 [-2.03, 1.52]

Use of galantamine

5 (0.17)

Secondary sideroblastic anaemia

0 (0.00)

-0.19 [-1.02, 0.64]

Benign neoplasm: Liver/bile ducts (ICD-9)

Benign neoplasms

131 (0.09)

Alcoholic cardiomyopathy

0 (0.00)

-0.23 [-1.11, 0.64]

Dislocation, sprain and strain of joint and ligaments of hip

Disorders of aromatic amino-acid metabolism

0 (0.00)

0.87 [-0.58, 2.32]

Benign neoplasm: Uterine tubes and ligaments

0 (0.00)

Third [oculomotor] nerve palsy

-0.05 [-2.12, 2.03]

Ototoxic hearing loss

-0.46 [-1.38, 0.47]

Deficiency of other B group vitamins

Primary_lymphoid and hematopoietic malignant neoplasms

15 (0.14)

-0.12 [-0.77, 0.52]

Acute myeloid leukaemia and myelodysplastic syndromes, excluding all cancers (controls excluding all cancers)

-0.21 [-1.61, 1.19]

Benign neoplasm: Other/unspecified site

0 (0.00)

Alkalosis

0 (0.00)

0.30 [-0.57, 1.17]

Primary biliary cholangitis (PBC)

0 (0.00)

-0.36 [-1.18, 0.45]

Malignant neoplasm of nasal cavity and middle ear, excluding all cancers (controls excluding all cancers)

0 (0.00)

Duodenal ulcer - Chronic or unspecified with perforation, drug-induced

Pedestrian injured in transport accident

0 (0.00)

Benign neoplasm: Cornea

Syndactyly

-0.06 [-0.64, 0.53]

Occupant of special vehicle mainly used on industrial premises injured in transport accident

0 (0.00)

Taeniasis

Alport

0 (0.00)

Other chondrocalcinosis

-0.63 [-1.75, 0.48]

Need for immunization against certain single viral diseases

0 (0.00)

Hypothyroidism, other/unspecified

59 (0.09)

Female infertility, uterine origin

0 (0.00)

-0.54 [-1.65, 0.57]

Other drug-induced secondary parkinsonism

0 (0.00)

0.19 [-0.85, 1.23]

Use of eteplirsen

Left side

0 (0.00)

Polyarteritis with lung involvement [Churg-Strauss]/EGPA

0 (0.00)

-0.10 [-0.77, 0.57]

Type 1 diabetes, wide definition, subgroup 1

10 (0.09)

Iliotibial band syndrome

-0.51 [-1.64, 0.62]

Flexion deformity

0 (0.00)

Preparation and fitting of bite rail to mouth

5 (0.08)

Typhoid and paratyphoid fevers

0 (0.00)

0.04 [-0.92, 0.99]

Contact with other hot fluids

Benign neoplasm: Short bones of lower limb

0 (0.00)

Guillain-Barre syndrome

0 (0.00)

-0.23 [-1.40, 0.94]

Otorrhoea

0 (0.00)

-0.17 [-1.07, 0.72]

Disseminated intravascular coagulation [defibrination syndrome]

0.11 [-0.71, 0.93]

Other congenital malformations of skull and face bones

0.33 [-0.43, 1.08]

Abnormal involuntary movements

9 (0.15)

Surgical ablation of atrial fibrillation

0 (0.00)

Glaucoma-related operations

7 (0.31)

Miliaria crystallina

Immunodeficiency following hereditary defective response to Epstein-Barr virus

Dietary calcium deficiency

Nondiabetic hypoglycaemic coma, drug-induced

Neuroendocrine tumor and carcinoma of rectum, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.12 [-0.78, 0.54]

Bacterial pneumonia (organism specified)

18 (0.08)

Other parasitologically confirmed or unspecified malaria

0.01 [-0.56, 0.58]

Systemic sclerosis, icd10

Hyperhidrosis

Carcinoma in situ of breast, other/unspecified

0 (0.00)

COPD, hospital admissions 1, only main diagnosis

15 (0.09)

Atypical mycobacterium lung infection

0 (0.00)

-1.00 [-2.99, 0.99]

Infliximab

0 (0.00)

Biliary cirrhosis, NAS

0 (0.00)

-0.89 [-2.22, 0.45]

Benign neoplasm: Respiratory system, unspecified

0 (0.00)

-0.09 [-0.84, 0.67]

Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

0 (0.00)

Localized skin eruption due to drugs and medicaments

0 (0.00)

0.78 [-1.03, 2.59]

L02BX Other hormone antagonists and related agents

0 (0.00)

Chronic lymphocytic leukaemia and small lyphocytis leukaemia, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.21 [-0.57, 1.00]

Hydatidiform mole

0 (0.00)

-0.75 [-2.51, 1.01]

Use of safinamide

Amiodarone users

7 (0.17)

Heart failure,strict

34 (0.09)

Familial erythrocytosis

-0.40 [-1.28, 0.48]

L04AD Calcineurin inhibitors

15 (0.33)

Isolated proteinuria with specified morphological lesion

0 (0.00)

0.13 [-0.88, 1.14]

Leukaemia of unspecified cell type

0 (0.00)

Pseudofolliculitis barbae

Neurological devices associated with adverse incidents

0 (0.00)

Caught, crushed, jammed or pinched in or between objects

0 (0.00)

Malignant neoplasm of pyriform sinus

Dissocial personality disorder

-0.45 [-1.36, 0.46]

Folliculitis decalvans

0 (0.00)

-0.07 [-0.69, 0.55]

Pemphigus vegetans

Benign neoplasm: Trachea

Nephrotic syndrome, drug-induced

0 (0.00)

Other congenital malformations of kidney

0.36 [-0.58, 1.31]

Sleep disorders, other/unspecified

0 (0.00)

0.37 [-0.88, 1.62]

Death from sequelae of obstetric causes

Symptoms and signs involving the circulatory and respiratory systems

136 (0.08)

Open wound of forearm

Bus occupant injured in other and unspecified transport accidents

0 (0.00)

Injury of nerves and spinal cord at thorax level

0 (0.00)

Mandibular prognathia AND surgery (LeFortI or BSSO or LeFortI AND BSSO), including avohilmo

0 (0.00)

Serum neuropathy, drug-induced

Other specified and unspecified disorders of conjunctiva

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints